Mylan II B.V. 10-Q6 Nov 202020 Q3 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - $ / shares	9 Months Ended
Cover Page - $ / shares	Sep. 30, 2020	Oct. 31, 2020	Dec. 31, 2019
Cover [Abstract]
Entity Address, Address Line One	Building 4
Title of 12(b) Security	Ordinary shares, nominal value €0.01
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	P7
Entity Tax Identification Number	98-1493528
Entity File Number	333-199861
Entity Registrant Name	MYLAN N.V.
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Entity Filler Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Ordinary Shares, Shares Outstanding		541,545,862
Ordinary shares nominal value (in Euro's per share)	$ 0.01		$ 0.01
Trading Symbol	MYL
Security Exchange Name	NASDAQ
Entity Address, Address Line Two	Trident Place
Entity Address, Address Line Three	Mosquito Way
Entity Address, City or Town	Hatfield
Entity Address, Postal Zip Code	AL10 9UL
Entity Address, Country	GB
Country Region	44
City Area Code	1707
Local Phone Number	853-000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Central Index Key	0001623613
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net sales	$ 2,948.1	$ 2,928.2	$ 8,232.2	$ 8,207
Total revenues	2,972.1	2,961.7	8,322.5	8,308.7
Cost of sales	1,813.6	1,889.3	5,232.2	5,498.5
Gross profit	1,158.5	1,072.4	3,090.3	2,810.2
Operating expenses:
Research and development	129.8	167.9	400.3	488.1
Selling, general and administrative	658.4	632.7	1,983.2	1,909.2
Litigation settlements and other contingencies, net	18.9	(51.9)	36.5	(30.3)
Total operating expenses	807.1	748.7	2,420	2,367
Earnings from operations	351.4	323.7	670.3	443.2
Interest expense	117.3	128.9	353.4	391.3
Other (income) expense, net	(7.5)	9	24.6	32.7
Earnings before income taxes	241.6	185.8	292.3	19.2
Income tax provision (benefit)	55.9	(4)	46.4	22.9
Net earnings (loss)	$ 185.7	$ 189.8	$ 245.9	$ (3.7)
Earnings (Loss) per ordinary share:
Basic (in USD per share)	$ 0.36	$ 0.37	$ 0.48	$ (0.01)
Diluted (in USD per share)	$ 0.36	$ 0.37	$ 0.48	$ (0.01)
Weighted average ordinary shares outstanding:
Basic	516.9	516	516.8	515.5
Diluted	517.7	516.2	517.3	515.5
Other Revenues
Total revenues	$ 24	$ 33.5	$ 90.3	$ 101.7

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Comprehensive Earnings (Loss) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net earnings (loss)	$ 185.7	$ 189.8	$ 245.9	$ (3.7)
Other comprehensive earnings (loss), before tax:
Foreign currency translation adjustment	687.7	(748.9)	483.1	(890.8)
Change in unrecognized (loss) gain and prior service cost related to defined benefit plans	(1.6)	(0.7)	3.4	(0.5)
Net unrealized gain on marketable securities	0	0.1	0.8	0.7
Other comprehensive earnings (loss), before tax	603.9	(648.3)	367.4	(732.2)
Income tax provision (benefit)	2.8	1.2	(6)	14.1
Other comprehensive earnings (loss), net of tax	601.1	(649.5)	373.4	(746.3)
Comprehensive earnings (loss)	786.8	(459.7)	619.3	(750)
Cash Flow Hedging
Other comprehensive earnings (loss), before tax:
Other comprehensive income (loss), derivatives qualifying as hedges, before tax	32.5	(10.6)	(0.2)	24.8
Net Investment Hedging
Other comprehensive earnings (loss), before tax:
Other comprehensive income (loss), derivatives qualifying as hedges, before tax	$ (114.7)	$ 111.8	$ (119.7)	$ 133.6

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 664.5	$ 475.6
Accounts receivable, net	2,964.1	3,058.8
Inventories	3,022	2,670.9
Prepaid expenses and other current assets	684.1	552
Total current assets	7,334.7	6,757.3
Property, plant and equipment, net	2,058.3	2,149.6
Intangible assets, net	10,965.8	11,649.9
Goodwill	9,817.3	9,590.6
Deferred income tax benefit	658.1	703.1
Other assets	408.9	405
Total assets	31,243.1	31,255.5
Current liabilities:
Accounts payable	1,447.8	1,528.1
Short-term borrowings	0.3	0
Income taxes payable	343.3	213
Current portion of long-term debt and other long-term obligations	3,237.8	1,508.1
Other current liabilities	2,246.2	2,319.9
Total current liabilities	7,275.4	5,569.1
Long-term debt	9,101.5	11,214.3
Deferred income tax liability	1,417.4	1,627.5
Other long-term obligations	900.9	960.8
Total liabilities	18,695.2	19,371.7
Mylan N.V. shareholders’ equity
Ordinary shares	6.1	6.1
Additional paid-in capital	8,688.3	8,643.5
Retained earnings	6,277	6,031.1
Accumulated other comprehensive loss	(1,423.8)	(1,797.2)
Total Mylan N.V. equity, before treasury stock	13,547.6	12,883.5
Less: Treasury stock — at cost	999.7	999.7
Total equity	12,547.9	11,883.8
Total liabilities and equity	$ 31,243.1	$ 31,255.5

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Ordinary shares nominal value (in Euro's per share)	$ 0.01	$ 0.01
Ordinary shares authorized, shares	1,200,000,000	1,200,000,000
Ordinary shares issued, shares	541,550,055	540,746,871

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($)	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings	Retained EarningsCumulative Effect, Period of Adoption, Adjustment	Treasury Stock [Member]	Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive LossCumulative Effect, Period of Adoption, Adjustment
Balance at Dec. 31, 2018	$ 12,167,100,000		$ 6,000,000	$ 8,591,400,000	$ 6,010,700,000		$ (999,700,000)	$ (1,441,300,000)
Balance (in shares) at Dec. 31, 2018			539,289,665
Balance (in shares) at Dec. 31, 2018							23,490,867
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	(3,700,000)
Other comprehensive loss, net of tax	(746,300,000)							(746,300,000)
Stock options exercised, net of shares tendered for payment (in shares)			1,449,836
Issuance of restricted stock, net of shares withheld	8,100,000			8,100,000
Taxes related to the net share settlement of equity awards	(12,800,000)			(12,800,000)
Stock compensation expense	50,900,000			50,900,000
Balance at Sep. 30, 2019	11,463,400,000		$ 6,100,000	8,637,600,000	6,010,600,000		$ (999,700,000)	(2,191,200,000)
Balance (in shares) at Sep. 30, 2019			540,739,501
Balance (in shares) at Sep. 30, 2019							24,598,074
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	$ (3,700,000)
Treasury Stock, Shares, Retired	100,000		100,000				1,107,207
Balance at Jun. 30, 2019	$ 11,902,800,000	$ 0	$ 6,100,000	8,617,300,000	5,820,800,000	$ 3,600,000	$ (999,700,000)	(1,541,700,000)	$ (3,600,000)
Balance (in shares) at Jun. 30, 2019			540,459,996
Balance (in shares) at Jun. 30, 2019							24,598,074
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	189,800,000
Other comprehensive loss, net of tax	(649,500,000)							(649,500,000)
Stock options exercised, net of shares tendered for payment (in shares)			279,505
Issuance of restricted stock, net of shares withheld	4,200,000			4,200,000
Stock compensation expense	16,100,000			16,100,000
Balance at Sep. 30, 2019	11,463,400,000		$ 6,100,000	8,637,600,000	6,010,600,000		$ (999,700,000)	(2,191,200,000)
Balance (in shares) at Sep. 30, 2019			540,739,501
Balance (in shares) at Sep. 30, 2019							24,598,074
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	189,800,000
Balance at Dec. 31, 2019	$ 11,883,800,000		$ 6,100,000	8,643,500,000	6,031,100,000		$ (999,700,000)	(1,797,200,000)
Balance (in shares) at Dec. 31, 2019	540,746,871
Balance (in shares) at Dec. 31, 2019							24,598,074
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	$ 245,900,000
Other comprehensive loss, net of tax	373,400,000							373,400,000
Stock options exercised, net of shares tendered for payment (in shares)			803,184
Issuance of restricted stock, net of shares withheld	600,000		$ 0	600,000
Taxes related to the net share settlement of equity awards	(5,600,000)			(5,600,000)
Stock compensation expense	49,800,000			49,800,000
Balance at Sep. 30, 2020	$ 12,547,900,000		6,100,000	8,688,300,000	6,277,000,000		$ (999,700,000)	(1,423,800,000)
Balance (in shares) at Sep. 30, 2020	541,550,055
Balance (in shares) at Sep. 30, 2020							24,598,074
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	$ 245,900,000
Balance at Jun. 30, 2020	11,746,200,000		$ 6,100,000	8,673,200,000	6,091,500,000		$ (999,700,000)	(2,024,900,000)
Balance (in shares) at Jun. 30, 2020			541,545,308
Balance (in shares) at Jun. 30, 2020							24,598,074
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	185,700,000
Other comprehensive loss, net of tax	601,100,000							601,100,000
Stock options exercised, net of shares tendered for payment (in shares)			4,747
Issuance of restricted stock, net of shares withheld	0		$ 0	0
Stock compensation expense	15,100,000			15,100,000
Balance at Sep. 30, 2020	$ 12,547,900,000		$ 6,100,000	$ 8,688,300,000	$ 6,277,000,000		$ (999,700,000)	$ (1,423,800,000)
Balance (in shares) at Sep. 30, 2020	541,550,055
Balance (in shares) at Sep. 30, 2020							24,598,074
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Other	$ (200,000)
Net earnings (loss)	$ 185,700,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net earnings (loss)	$ 245.9	$ (3.7)
Adjustments to reconcile net earnings (loss) to net cash provided by operating activities:
Depreciation and amortization	1,263	1,471.6
Share-based Compensation	49.8	50.9
Deferred income tax benefit	(210.4)	(158)
Loss from equity method investments	37.4	43.6
Other non-cash items	134.3	124.2
Litigation settlements and other contingencies, net	43.6	13.5
Changes in operating assets and liabilities:
Accounts receivable	(27.3)	(20.7)
Inventories	(532.4)	(477.6)
Accounts payable	(99.7)	(83.2)
Income taxes	115.2	(60.2)
Other operating assets and liabilities, net	176.2	216.6
Net cash provided by operating activities	1,195.6	1,117
Cash flows from investing activities:
Cash paid for acquisitions, net	0	(148.7)
Capital expenditures	(126.1)	(139.6)
Purchase of available for sale securities and other investments	(96.1)	(19.5)
Proceeds from the sale of marketable securities	38.6	19.1
Payments for product rights and other, net	(97.3)	(146.5)
Proceeds from the sale of assets	2.1	24.3
Net cash used in investing activities	(278.8)	(410.9)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	33.2	6.4
Payments of long-term debt	(588.9)	(657.1)
Non-contingent payments for product rights	(139.5)	0
Change in short-term borrowings, net	0.3	(1.9)
Taxes paid related to net share settlement of equity awards	(7.1)	(8.4)
Contingent consideration payments	(48.5)	(47.8)
Payments of financing fees	(1.8)	(2.7)
Proceeds from exercise of stock options	0.6	8
Other items, net	(3.1)	(1.1)
Net cash used in financing activities	(754.8)	(704.6)
Effect on cash of changes in exchange rates	14	(16.4)
Net increase (decrease) in cash, cash equivalents and restricted cash	176	(14.9)
Cash, cash equivalents and restricted cash — beginning of period	491.1	389.3
Cash, cash equivalents and restricted cash — end of period	$ 667.1	$ 374.4

Collaboration and Licensing Agr

Collaboration and Licensing Agreements	9 Months Ended
Collaboration and Licensing Agreements	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and Licensing Agreements	Collaboration and Licensing Agreements We periodically enter into collaboration and licensing agreements with other pharmaceutical companies for the development, manufacture, marketing and/or sale of pharmaceutical products. Our significant collaboration agreements are primarily focused on the development, manufacturing, supply and commercialization of multiple, high-value generic biologic compounds, insulin analog products and respiratory products, among other complex products. Under these agreements, we have future potential milestone payments and co-development expenses payable to third parties as part of our licensing, development and co-development programs. Payments under these agreements generally become due and are payable upon the satisfaction or achievement of certain developmental, regulatory or commercial milestones or as development expenses are incurred on defined projects. Milestone payment obligations are uncertain, including the prediction of timing and the occurrence of events triggering a future obligation and are not reflected as liabilities in the condensed consolidated balance sheets, except for obligations reflected as acquisition related contingent consideration. Refer to Note 11 Financial Instruments and Risk Management for further discussion of contingent consideration. Our potential maximum development milestones not accrued for at September 30, 2020 totaled approximately $425 million . We estimate that the amounts that may be paid during the next twelve months to be approximately $40 million. These agreements may also include potential sales-based milestones and call for us to pay a percentage of amounts earned from the sale of the product as a royalty or a profit share. The amounts disclosed do not include sales-based milestones or royalty or profit share obligations on future sales of product as the timing and amount of future sales levels and costs to produce products subject to these obligations is not reasonably estimable. These sales-based milestones or royalty or profit share obligations may be significant depending upon the level of commercial sales for each product. On February 28, 2018, the Company and Revance Therapeutics, Inc. (“Revance”) entered into a collaboration agreement (the “Revance Collaboration Agreement”) pursuant to which the Company and Revance will collaborate exclusively, on a world-wide basis (excluding Japan), to develop, manufacture and commercialize a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX®. On August 22, 2019, the Company and Revance entered into an amendment (the “Amendment”) to the Revance Collaboration Agreement, pursuant to which Revance had agreed to extend the period of time for the Company to decide whether to continue the development and commercialization of a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX® beyond the initial development plan to prepare for and conduct the Biosimilar Initial Advisory Meeting (BIAM) with the U.S. Food and Drug Administration (“FDA”). In accordance with the Amendment, the Company was required to notify Revance of its decision on or before the later of (i) April 30, 2020 or (ii) thirty calendar days from the date that Revance provides Mylan with certain deliverables. On June 1, 2020, the Company and Revance announced a decision to continue the development program for a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX®. As a result, during the nine months ended September 30, 2020, the Company recorded $30 million of R&D expense for a milestone payment that was due upon the decision to continue the program. There have been no other significant changes to our collaboration and licensing agreements as disclosed in our 2019 Form 10-K.

General

General	9 Months Ended
General	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	General The accompanying unaudited condensed consolidated financial statements (“interim financial statements”) of Mylan N.V. and subsidiaries (“Mylan” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in audited financial statements were condensed or omitted. The interim financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the interim results of operations, comprehensive earnings, financial position, equity and cash flows for the periods presented. The global spread of the coronavirus disease 2019 (“COVID-19”) has created significant volatility, uncertainty and economic disruption affecting the markets we serve in North America, Europe and Rest of World, including Asia. Certain significant impacts of COVID-19 on our business are discussed in these notes to the condensed consolidated financial statements. These interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto in Mylan N.V.’s Annual Report on Form 10-K for the year ended December 31, 2019, as amended (the “2019 Form 10-K”). The December 31, 2019 condensed consolidated balance sheet was derived from audited financial statements. The interim results of operations and comprehensive earnings (loss) for the three and nine months ended September 30, 2020, and cash flows for the nine months ended September 30, 2020, are not necessarily indicative of the results to be expected for the full fiscal year or any other future period.

Revenue Recognition and Account

Revenue Recognition and Accounts Receivable	9 Months Ended
Revenue Recognition and Accounts Receivable	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue Recognition and Accounts Receivable	Revenue Recognition and Accounts Receivable The Company recognizes revenue in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the condensed consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Our net sales may be impacted by wholesaler and distributor inventory levels of our products, which can fluctuate throughout the year due to the seasonality of certain products, pricing, the timing of product demand, customer purchasing decisions and other factors. Such fluctuations may impact the comparability of our net sales between periods. Consideration received from licenses of intellectual property is recorded as other revenues. Royalty or profit share amounts, which are based on sales of licensed products or technology, are recorded when the customer’s subsequent sales or usages occur. Such consideration is included in other revenue in the condensed consolidated statements of operations. The following table presents the Company’s net sales by therapeutic franchise for each of our reportable segments for the three and nine months ended September 30, 2020 and 2019, respectively: (In millions) North America Europe Rest of World Total Three Months Ended September 30, 2020 Central Nervous System & Anesthesia $ 181.8 $ 211.5 $ 81.1 $ 474.4 Infectious Disease 37.3 197.2 272.6 507.1 Respiratory & Allergy 284.9 103.1 74.4 462.4 Cardiovascular 58.5 125.6 38.4 222.5 Gastroenterology 41.8 166.2 91.7 299.7 Diabetes & Metabolism 70.8 80.1 36.3 187.2 Dermatology 33.2 72.8 20.3 126.3 Women’s Healthcare 96.0 60.5 34.0 190.5 Oncology 171.4 30.4 40.0 241.8 Immunology 7.9 35.2 10.2 53.3 Other (1) 45.2 41.2 96.5 182.9 Total $ 1,028.8 $ 1,123.8 $ 795.5 $ 2,948.1 Nine Months Ended September 30, 2020 Central Nervous System & Anesthesia $ 484.0 $ 631.0 $ 210.8 $ 1,325.8 Infectious Disease 120.7 320.1 756.8 1,197.6 Respiratory & Allergy 890.4 362.3 165.6 1,418.3 Cardiovascular 184.4 372.7 102.9 660.0 Gastroenterology 121.0 465.6 252.6 839.2 Diabetes & Metabolism 187.4 231.7 89.7 508.8 Dermatology 87.8 215.0 57.2 360.0 Women’s Healthcare 275.9 180.6 84.9 541.4 Oncology 470.8 71.2 103.8 645.8 Immunology 26.9 88.3 27.2 142.4 Other (1) 174.0 142.2 276.7 592.9 Total $ 3,023.3 $ 3,080.7 $ 2,128.2 $ 8,232.2 (In millions) North America Europe Rest of World Total Three Months Ended September 30, 2019 Central Nervous System & Anesthesia $ 155.5 $ 214.3 $ 87.0 $ 456.8 Infectious Disease 28.7 179.0 270.3 478.0 Respiratory & Allergy 308.5 98.2 66.6 473.3 Cardiovascular 63.3 126.2 41.3 230.8 Gastroenterology 30.0 147.9 95.9 273.8 Diabetes & Metabolism 91.3 68.9 34.2 194.4 Dermatology 38.2 75.8 29.3 143.3 Women’s Healthcare 100.4 60.5 26.1 187.0 Oncology 196.1 22.0 42.8 260.9 Immunology 12.3 20.3 10.3 42.9 Other (1) 64.3 32.8 89.9 187.0 Total $ 1,088.6 $ 1,045.9 $ 793.7 $ 2,928.2 Nine Months Ended September 30, 2019 Central Nervous System & Anesthesia $ 426.4 $ 619.3 $ 243.9 $ 1,289.6 Infectious Disease 77.3 299.7 783.0 1,160.0 Respiratory & Allergy 805.3 327.9 166.5 1,299.7 Cardiovascular 159.1 358.6 116.1 633.8 Gastroenterology 94.9 434.9 276.3 806.1 Diabetes & Metabolism 326.1 208.0 110.4 644.5 Dermatology 77.6 217.7 70.7 366.0 Women’s Healthcare 269.5 165.3 65.4 500.2 Oncology 567.8 59.9 107.0 734.7 Immunology 31.4 41.3 27.6 100.3 Other (1) 199.6 198.1 274.4 672.1 Total $ 3,035.0 $ 2,930.7 $ 2,241.3 $ 8,207.0 ____________ (1) Other consists of numerous therapeutic franchises, none of which individually exceeds 5% of consolidated net sales. Variable Consideration and Accounts Receivable The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the three and nine months ended September 30, 2020 and 2019, respectively: Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Gross sales $ 4,986.4 $ 5,051.5 $ 13,868.0 $ 13,841.0 Gross to net adjustments: Chargebacks (967.0) (913.5) (2,616.9) (2,368.8) Rebates, promotional programs and other sales allowances (926.3) (979.2) (2,592.3) (2,709.9) Returns (76.6) (82.3) (193.2) (203.3) Governmental rebate programs (68.4) (148.3) (233.4) (352.0) Total gross to net adjustments $ (2,038.3) $ (2,123.3) $ (5,635.8) $ (5,634.0) Net sales $ 2,948.1 $ 2,928.2 $ 8,232.2 $ 8,207.0 No significant revisions were made to the methodology used in determining these provisions or the nature of the provisions during the three and nine months ended September 30, 2020. Such allowances were comprised of the following at September 30, 2020 and December 31, 2019, respectively: (In millions) September 30, December 31, Accounts receivable, net $ 1,502.6 $ 1,512.0 Other current liabilities 697.9 796.5 Total $ 2,200.5 $ 2,308.5 Accounts receivable, net was comprised of the following at September 30, 2020 and December 31, 2019, respectively: (In millions) September 30, December 31, Trade receivables, net $ 2,587.8 $ 2,640.1 Other receivables 376.3 418.7 Accounts receivable, net $ 2,964.1 $ 3,058.8 Receivables Facility and Note Securitization Facility Through its wholly owned subsidiary Mylan Pharmaceuticals Inc., the Company has access to a $400 million accounts receivable securitization facility (the “Receivables Facility”) and a $200 million note securitization facility (the “Note Securitization Facility”). The receivables underlying any borrowings are included in accounts receivable, net, in the condensed consolidated balance sheets. There were $480.6 million and $407.0 million of securitized accounts receivable at September 30, 2020 and December 31, 2019, respectively. On August 4, 2020, the Company entered into (i) an amendment to the Receivables Facility to permit the occurrence of the Combination (as defined below) and to make certain other updates and (ii) an amendment to the Note Securitization Facility to extend the maturity date to August 30, 2021. We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $123.0 million and $90.1 million of accounts receivable as of September 30, 2020 and December 31, 2019, respectively, under these factoring arrangements.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
Recent Accounting Pronouncements	Sep. 30, 2020
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	Recent Accounting Pronouncements Adoption of New Accounting Standards and Amended SEC Rules In June 2016, the FASB issued Accounting Standards Update 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses (“ASU 2016-13”) , which requires an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. In May 2019, the FASB issued ASU 2019-05, Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relie f (“ASU 2019-05”). ASU 2019-05 provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of ASU 2016-13. The Company applied the provisions of ASU 2016-13 and its subsequent revisions as of January 1, 2020 and the adoption did not have a material impact on its condensed consolidated financial statements and disclosures. In August 2018, the FASB issued Accounting Standards Update 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-03”), which adds to and modifies certain disclosure requirements for fair value measurements including a requirement to disclose changes in unrealized gains and losses included in other comprehensive income for recurring Level 3 fair value measurements and a requirement to disclose the range and weighted average used to develop significant inputs for Level 3 fair value measurements. The Company applied the provisions of ASU 2018-13 as of January 1, 2020. The adoption of this guidance did not have a material impact on the Company’s disclosures. In August 2018, the FASB issued Accounting Standards Update 2018-15, Intangibles - Goodwill and Other - Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”). The objective of this update is to clarify and align the accounting and capitalization of implementation costs for hosting arrangements, regardless of whether they convey a license to the hosted software. The updated guidance will require an entity in a hosting arrangement that is a service contract, to follow guidance in ASC Topic 350, Intangibles-Goodwill and Other, to determine which implementation costs to capitalize as an asset and which costs to expense. The Company applied the provisions of ASU 2018-15 as of January 1, 2020. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements and disclosures. In November 2018, the FASB issued Accounting Standards Update 2018-18, Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606 (“ASU 2018-18”). The amendments in ASU 2018-18 make targeted improvements to U.S. GAAP for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in Topic 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in Topic 808 was aligned with the guidance in Topic 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of Topic 606. The Company applied the provisions of ASU 2018-18 as of January 1, 2020. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements and disclosures. In March 2020, the SEC amended Rule 3-10 of Regulation S-X regarding the financial disclosure requirements for guarantors and issuers of guaranteed securities registered or being registered. Among other things, the amendments narrow the circumstances that require separate financial statements of subsidiary issuers and guarantors and streamline the alternative disclosures required in lieu of those financial statements. The effective date of the amendment is January 4, 2021 with earlier voluntary compliance permitted. We have chosen to voluntarily comply with the amended rules effective during the three months ended March 31, 2020 and have included the required disclosures as a component of Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations of this Form 10-Q as permitted by the amendments. Accounting Standards Issued Not Yet Adopted In January 2020, the FASB issued Accounting Standards Update 2020-01, Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815 (“ASU 2020-01”) , which clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. In addition, ASU 2020-01 states that for the purpose of applying paragraph 815-10-15-141(a) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. ASU 2020-01 will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 with early adoption in any interim period permitted. The Company is currently assessing the impact of the adoption of this guidance on its condensed consolidated financial statements and disclosures. In March 2020, the FASB issued Accounting Standards Update 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”) , which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2020-04 applies only to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. Entities can apply the provisions of ASU 2020-04 immediately, as applicable, and generally the provisions of the guidance are available through December 31, 2022 as entities transition away from reference rates that are expected to be discontinued. The Company is currently assessing the impact of the adoption of this guidance on its condensed consolidated financial statements and disclosures. In addition, the following recently issued accounting standard has not been adopted. Refer to the 2019 Form 10-K for additional information and its potential impact. Accounting Standard Update Effective Date ASU 2018-14: Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20) Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans January 1, 2021

Acquisitions and Other Transact

Acquisitions and Other Transactions	9 Months Ended
Acquisitions and Other Transactions	Sep. 30, 2020
Business Combinations [Abstract]
Acquisitions and Other Transactions	Acquisitions and Other Transactions Upjohn Business Combination Agreement On July 29, 2019, the Company, Pfizer Inc. (“Pfizer”), Upjohn Inc., a wholly-owned subsidiary of Pfizer (“Upjohn” or “Newco”), and certain other affiliated entities entered into a Business Combination Agreement (as amended, the “Business Combination Agreement”) pursuant to which the Company will combine with Pfizer’s Upjohn Business (the “Upjohn Business”) in a Reverse Morris Trust transaction (the “Combination”). Newco, which will be the parent entity of the combined Upjohn Business and Mylan business, will be renamed Viatris Inc. (“Viatris”) effective as of the closing of the Combination. The Upjohn Business is a global, primarily off-patent branded and generic established medicines business, which includes 20 primarily off-patent solid oral dose legacy brands, such as Lyrica, Lipitor, Celebrex and Viagra. Prior to the Combination and pursuant to a Separation and Distribution Agreement (as amended, the “Separation Agreement”), dated as of July 29, 2019, between Pfizer and Newco, Pfizer will, among other things, transfer to Newco substantially all of the assets and liabilities comprising the Upjohn Business (the “Separation”) and, thereafter, Pfizer will distribute to Pfizer stockholders all of the issued and outstanding shares of Newco (the “Distribution”). When the Distribution and Combination are completed, Pfizer stockholders as of the record date of the Distribution will own 57% of the outstanding shares of Newco common stock, and Mylan shareholders as of immediately before the Combination will own 43% of the outstanding shares of Newco common stock, in each case on a fully diluted basis. Newco will make a cash payment to Pfizer equal to $12 billion, to be funded with the proceeds of debt incurred by Newco, as partial consideration for the contribution of the Upjohn Business from Pfizer to Newco. The consummation of the Combination is subject to the satisfaction (or, if applicable, valid waiver) of various conditions, including (a) the expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder and the receipt of regulatory approvals in certain other jurisdictions, (b) the consummation of the Separation and the Distribution in accordance with the terms of the Separation Agreement, (c) the approval of the Combination by Mylan shareholders, (d) the absence of any legal restraint (including legal actions or proceedings pursued by U.S. state authorities in the relevant states) preventing the consummation of the transactions, (e) in the case of Pfizer’s and Newco’s obligations to consummate the transactions, (i) the distribution of $12 billion in cash from Upjohn to Pfizer in accordance with the terms of the Separation Agreement and (ii) the receipt by Pfizer of a U.S. Internal Revenue Service (“IRS”) ruling and tax opinion of its tax counsel with respect to the Combination, and (f) other customary closing conditions. On March 17, 2020, Pfizer received the IRS ruling with respect to the Combination, which is generally binding, unless the relevant facts or circumstances change prior to closing. On June 30, 2020, Mylan’s shareholders voted to approve the Combination at the extraordinary general meeting of shareholders. On September 14, 2020, the European Commission (the “Commission”) approved the divestiture buyers with which Mylan entered into agreements for the sale of certain of Mylan’s products in Europe, which was a requirement of the Commission’s conditional approval of the Combination in April 2020. On October 30, 2020, Mylan and Pfizer announced that the U.S. Federal Trade Commission (the “FTC”) accepted a proposed consent order, which concluded the FTC’s review of the proposed Combination. The parties have now obtained all required antitrust clearances for the Combination. The Combination is expected to close on November 16, 2020. On May 29, 2020, Mylan, Pfizer, Newco and certain of their affiliates entered into Amendment No. 1 to the Business Combination Agreement (the “BCA Amendment”), and Pfizer and Newco entered into Amendment No. 2 to the Separation and Distribution Agreement (the “SDA Amendment” and, together with the BCA Amendment, the “Amendments”). In light of the ongoing regulatory review process, including delays related to the COVID-19 pandemic, the Amendments provide, among other things, that the closing of the Combination shall not occur prior to October 1, 2020 (unless otherwise agreed to by Mylan and Pfizer) and that the Outside Date (as defined in the Business Combination Agreement) shall be December 31, 2020. On June 16, 2020, Upjohn entered into a revolving credit agreement (the “Upjohn Revolving Credit Agreement”), by and among Upjohn, certain lenders and issuing banks from time to time party thereto and Bank of America, N.A., as administrative agent (in such capacity, the “Upjohn Revolving Administrative Agent”). The Upjohn Revolving Credit Agreement contains a revolving credit facility (the “Upjohn Revolving Credit Facility”) under which Upjohn may obtain extensions of credit in an aggregate principal amount not to exceed $4.0 billion, in U.S. dollars or alternative currencies including Euro, Sterling, Yen and any other currency that is approved by the Upjohn Revolving Administrative Agent and each lender under the Upjohn Revolving Credit Facility. The Upjohn Revolving Credit Facility will be available to Upjohn upon (a) its delivery of a certificate certifying that (i) the conditions to the consummation of the Combination have been satisfied or waived or are expected to be satisfied or waived on the date of funding of such facility or within one business day thereafter and (ii) the distribution by Pfizer to its stockholders of its shares of Upjohn’s common stock pursuant to the Separation Agreement is expected to be, the Combination is expected to be, and the contribution of the Upjohn Business to Upjohn has been or is expected to be consummated on the Upjohn Revolver Closing Date (as defined below) or within one business day thereafter (an “RMT Condition Certificate”) and (b) the satisfaction of certain customary conditions (the date such conditions are satisfied or waived being referred to as the “Upjohn Revolver Closing Date”). Subject to satisfaction of the foregoing conditions, up to $1.5 billion under the Upjohn Revolving Credit Facility will be available to Upjohn in a single draw on the Upjohn Revolver Closing Date for the sole purpose of funding a portion of the cash payment of $12.0 billion by Upjohn to Pfizer as partial consideration for Pfizer’s contribution of the Upjohn Business to Upjohn, as required by the Separation Agreement. On June 16, 2020, Upjohn entered into a delayed draw term loan credit agreement (the “Upjohn Term Loan Credit Agreement”), by and among Upjohn, Mizuho Bank, Ltd. and MUFG Bank, Ltd., as administrative agent. The Upjohn Term Loan Credit Agreement provides for an 18-month $600.0 million principal amount delayed draw senior unsecured term loan facility (the “Upjohn Term Loan Credit Facility”). The Upjohn Term Loan Credit Facility will be available to Upjohn upon its delivery of an RMT Condition Certificate and upon satisfaction of certain customary conditions. Upjohn intends to borrow the full $600.0 million aggregate principal amount available under the Upjohn Term Loan Credit Facility in order to fund a portion of the cash payment to Pfizer and related transaction fees and expenses, as required by the Separation Agreement. On June 22, 2020, Upjohn completed a private offering of $7.45 billion aggregate principal amount of Upjohn’s senior, U.S. dollar-denominated notes (the “Upjohn U.S. Dollar Notes”) and on June 23, 2020, Upjohn Finance B.V. (“Finco”), a wholly-owned financing subsidiary of Upjohn, completed a private offering of €3.60 billion aggregate principal amount of Finco’s senior, euro-denominated notes (the “Upjohn Euro Notes” and, together with the Upjohn U.S. Dollar Notes, the “Upjohn Notes”), which are guaranteed on a senior unsecured basis by Upjohn. Upjohn intends to use the net proceeds from the offerings of the Upjohn Notes, together with the net proceeds from the Upjohn Term Loan Credit Facility, to fund in full the $12.0 billion cash payment to Pfizer and related transaction fees and expenses. The Upjohn Notes are initially guaranteed on a senior unsecured basis by Pfizer, which guarantees will be automatically and unconditionally terminated and released without consent of holders upon the consummation of the Distribution. Upon the consummation of the Combination, the Mylan entities (which will be subsidiaries of Upjohn following the Combination) that are issuers or guarantors of the outstanding senior unsecured notes issued by Mylan N.V. or Mylan Inc. (the “Mylan Notes”) will become guarantors of the Upjohn Notes, substantially concurrently with Upjohn becoming a guarantor of the Mylan Notes. Upjohn had previously obtained commitments for the initial financing of the transaction in the form of a bridge loan from certain financial institutions. The bridge loan was subject to customary terms and conditions including a financial covenant. The commitments under the bridge loan commitment letter dated as of July 29, 2019 were reduced concurrently with the effectiveness of the Upjohn Revolving Credit Agreement and Upjohn Term Loan Credit Agreement, and were fully terminated upon the completion of each offering of Upjohn Notes. Under the terms of the Business Combination Agreement and Separation Agreement, Mylan will be obligated to reimburse Pfizer for 43% of certain financing related costs if the Combination does not close and Viatris will be obligated to reimburse Pfizer for all such financing related costs if the Combination closes. As a result of the completion of the financing transactions described above, Mylan recorded $30.0 million and $115.0 million of expenses during the three and nine months ended September 30, 2020, respectively, which is included as a component of selling, general and administrative expenses (“SG&A”) in the condensed consolidated statements of operations to reflect Mylan’s obligation to reimburse Pfizer for 43% of those financing related costs. In connection with the Separation Agreement and the Business Combination Agreement, Pfizer, Upjohn and Mylan previously agreed to review and negotiate a potential transfer of Pfizer’s Meridian Medical Technologies business (the “Meridian Business”) to Upjohn. The Meridian Business is Mylan’s supplier of EpiPen® Auto-Injectors pursuant to an agreement that had an expiration date of December 31, 2020 (the “EpiPen Supply Agreement”). Instead of proceeding with the transfer of the Meridian Business, Pfizer and Mylan agreed in the third quarter of 2020 to extend the EpiPen Supply Agreement for an additional four-year period through December 31, 2024, with an option for Mylan (or Upjohn) to further extend the term for an additional one-year period thereafter. Mylan and Pfizer have also reached a preliminary agreement on the general terms under which Pfizer would transfer certain Pfizer assets that currently form part of a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan to Mylan or, following the Combination, to Viatris. Any such proposed transaction would be subject to the finalization and execution of a definitive agreement that would contain customary closing conditions including, but not limited to, receipt of any necessary regulatory approvals. Other Transactions During the three months ended September 30, 2020 the Company entered into an agreement to acquire the related intellectual property and commercialization rights of Aspen Global Incorporated’s (“Aspen”) thrombosis business in Europe for € 641.9 million, subject to customary closing conditions and European regulatory clearances. The portfolio consists of well-established injectable anticoagulants sold in Europe under the brand names, and variations of the brand names, Arixtra, Fraxiparine, Mono-Embolex and Orgaran. Upon closing of the transaction, the Company will make a payment of €263.2 million to Aspen with the remaining payment of €378.7 million due on June 25, 2021. The Commission approved the transaction on October 15, 2020, and the closing is expected to be completed in the fourth quarter of 2020.

Share-Based Incentive Plan

Share-Based Incentive Plan	9 Months Ended
Share-Based Incentive Plan	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Share-Based Incentive Plan	Share-Based Incentive Plan The Company’s shareholders have approved the 2003 Long-Term Incentive Plan (as amended, the “2003 Plan”). Under the 2003 Plan, 55,300,000 ordinary shares are reserved for issuance to key employees, consultants, independent contractors and non-employee directors of the Company through a variety of incentive awards, including: stock options, stock appreciation rights (“SAR”), restricted ordinary shares and units, performance awards (“PSU”), other stock-based awards and short-term cash awards. Stock option awards are granted with an exercise price equal to the fair market value of the ordinary shares underlying the stock options at the date of the grant, generally become exercisable over periods ranging from three The following table summarizes stock option and SAR (together, “stock awards”) activity: Number of Shares Under Stock Awards Weighted Average Exercise Price per Share Outstanding at December 31, 2019 6,347,709 $ 36.97 Granted 814,351 17.37 Exercised (27,615) 21.13 Forfeited (337,285) 25.37 Outstanding at September 30, 2020 6,797,160 $ 35.26 Vested and expected to vest at September 30, 2020 6,589,725 $ 35.57 Exercisable at September 30, 2020 5,159,754 $ 38.75 As of September 30, 2020, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had average remaining contractual terms of 5.3 years, 5.2 years and 4.2 years, respectively. Also, at September 30, 2020, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had no aggregate intrinsic values. A summary of the status of the Company’s nonvested restricted stock unit awards, including PSUs (collectively, “restricted stock awards”), as of September 30, 2020 and the changes during the nine months ended September 30, 2020 are presented below: Number of Restricted Stock Awards Weighted Average Grant-Date Fair Value per Share Nonvested at December 31, 2019 4,105,689 $ 34.42 Granted 2,978,412 17.46 Released (1,104,737) 36.57 Forfeited (306,108) 39.50 Nonvested at September 30, 2020 5,673,256 $ 24.83 As of September 30, 2020, the Company had $78.9 million of total unrecognized compensation expense, net of estimated forfeitures, related to all of its stock-based awards, which we expect to recognize over the remaining weighted average vesting period of 1.5 years. The total intrinsic value of stock awards exercised and restricted stock units released during the nine months ended September 30, 2020 and 2019 was $19.1 million and $37.9 million, respectively.

Pensions and Other Postretireme

Pensions and Other Postretirement Benefits	9 Months Ended
Pensions and Other Postretirement Benefits	Sep. 30, 2020
Retirement Benefits [Abstract]
Pension and Other Postretirement Benefits Disclosure	Pensions and Other Postretirement Benefits Defined Benefit Plans The Company sponsors various defined benefit pension plans in several countries. Benefits provided generally depend on length of service, pay grade and remuneration levels. The Company maintains two fully frozen defined benefit pension plans in the U.S., and employees in the U.S. and Puerto Rico are generally provided retirement benefits through defined contribution plans. The Company also sponsors other postretirement benefit plans including plans that provide for postretirement supplemental medical coverage. Benefits from these plans are provided to employees and their spouses and dependents who meet various minimum age and service requirements. In addition, the Company sponsors other plans that provide for life insurance benefits and postretirement medical coverage for certain officers and management employees. Net Periodic Benefit Cost Components of net periodic benefit cost for the three and nine months ended September 30, 2020 and 2019 were as follows: Pension and Other Postretirement Benefits Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Service cost $ 5.3 $ 5.3 $ 15.9 $ 15.9 Interest cost 2.9 3.8 8.7 11.5 Expected return on plan assets (3.3) (3.0) (10.1) (9.1) Amortization of prior service costs — 0.3 — 0.8 Recognized net actuarial losses (gains) 0.1 (0.2) 0.4 (0.6) Net periodic benefit cost $ 5.0 $ 6.2 $ 14.9 $ 18.5 The Company is making the minimum mandatory contributions to its U.S. defined benefit pension plans in the 2020 plan year. The Company expects to make total benefit payments of approximately $35.2 million from pension and other postretirement benefit plans in 2020. The Company anticipates making contributions to pension and other postretirement benefit plans of approximately $35.1 million in 2020.

Balance Sheet Components

Balance Sheet Components	9 Months Ended
Balance Sheet Components	Sep. 30, 2020
Balance Sheet Components [Abstract]
Balance Sheet Components	Balance Sheet Components Selected balance sheet components consist of the following: Cash and restricted cash (In millions) September 30, December 31, September 30, Cash and cash equivalents $ 664.5 $ 475.6 $ 358.9 Restricted cash, included in prepaid expenses and other current assets 2.6 15.5 15.5 Cash, cash equivalents and restricted cash $ 667.1 $ 491.1 $ 374.4 Inventories (In millions) September 30, December 31, Raw materials $ 892.6 $ 886.8 Work in process 426.6 417.2 Finished goods 1,702.8 1,366.9 Inventories $ 3,022.0 $ 2,670.9 Prepaid and other current assets (In millions) September 30, December 31, 2019 Prepaid expenses $ 189.1 $ 156.7 Restricted cash 2.6 15.5 Available-for-sale fixed income securities 39.1 26.8 Fair value of financial instruments 51.1 43.3 Equity securities 40.9 39.0 Other current assets 361.3 270.7 Prepaid expenses and other current assets $ 684.1 $ 552.0 Prepaid expenses consist primarily of prepaid rent, insurance and other individually insignificant items. Property, plant and equipment, net (In millions) September 30, December 31, 2019 Machinery and equipment $ 2,603.1 $ 2,523.7 Buildings and improvements 1,219.8 1,197.3 Construction in progress 271.9 277.3 Land and improvements 125.5 124.6 Gross property, plant and equipment 4,220.3 4,122.9 Accumulated depreciation 2,162.0 1,973.3 Property, plant and equipment, net $ 2,058.3 $ 2,149.6 Other assets (In millions) September 30, December 31, 2019 Equity method investments, clean energy investments $ 57.6 $ 92.2 Operating lease right-of-use assets 227.9 254.6 Other long-term assets 123.4 58.2 Other assets $ 408.9 $ 405.0 Accounts payable (In millions) September 30, December 31, Trade accounts payable $ 900.8 $ 1,061.9 Other payables 547.0 466.2 Accounts payable $ 1,447.8 $ 1,528.1 Other current liabilities (In millions) September 30, December 31, 2019 Accrued sales allowances $ 697.9 $ 796.5 Legal and professional accruals, including litigation accruals 117.5 138.2 Payroll and employee benefit liabilities 503.2 467.1 Contingent consideration 124.8 120.4 Accrued interest 179.1 59.1 Restructuring 17.1 26.0 Equity method investments, clean energy investments 50.1 47.7 Fair value of financial instruments 17.1 12.9 Operating lease liability 68.5 76.7 Other 470.9 575.3 Other current liabilities $ 2,246.2 $ 2,319.9 Other long-term obligations (In millions) September 30, December 31, 2019 Employee benefit liabilities $ 412.2 $ 408.9 Contingent consideration 88.4 130.3 Equity method investments, clean energy investments 13.5 57.2 Tax related items, including contingencies 137.3 109.6 Operating lease liability 156.9 175.7 Other 92.6 79.1 Other long-term obligations $ 900.9 $ 960.8

Equity Method Investments

Equity Method Investments	9 Months Ended
Equity Method Investments	Sep. 30, 2020
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments	Equity Method InvestmentsThe Company currently has three equity method investments in limited liability companies that own refined coal production plants (the “clean energy investments”) whose activities qualify for income tax credits under Section 45 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). During the three months ended September 30, 2020 and 2019, the Company reduced its long-term obligations for its three investments as a result of lower than anticipated production levels and lower expected future variable debt payments to the respective project sponsor. The Company recognized a net gain of approximately $15 million and $7 million, respectively, which was recognized as a component of the net loss of the equity method investments in the condensed consolidated statements of operations. Summarized financial information, in the aggregate, for the Company’s significant equity method investments on a 100% basis for the three and nine months ended September 30, 2020 and 2019 are as follows: Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Total revenues $ 113.5 $ 101.6 $ 288.8 $ 274.1 Gross loss (1.4) (1.1) (3.6) (3.1) Operating and non-operating expense 5.2 5.2 14.4 14.3 Net loss $ (6.6) $ (6.3) $ (18.0) $ (17.4) The Company’s net losses from its equity method investments include amortization expense related to the excess of the cost basis of the Company’s investment over the underlying assets of each individual investee. For the three months ended September 30, 2020 and 2019, the Company recognized net losses from equity method investments of $2.9 million and $10.4 million, respectively. For the nine months ended September 30, 2020 and 2019, the Company recognized net losses from equity method investments of $37.4 million and $43.6 million, respectively, which were recognized as a component of other expense, net in the condensed consolidated statements of operations. The Company recognizes the income tax credits and benefits from the clean energy investments as part of its provision for income taxes.

Earnings (Loss) per Ordinary Sh

Earnings (Loss) per Ordinary Share	9 Months Ended
Earnings (Loss) per Ordinary Share	Sep. 30, 2020
Earnings Per Share [Abstract]
Earnings (Loss) per Ordinary Share	Earnings (Loss) per Ordinary ShareBasic earnings (loss) per ordinary share is computed by dividing net earnings (loss) by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per ordinary share is computed by dividing net earnings (loss) by the weighted average number of ordinary shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive. Basic and diluted earnings (loss) per ordinary share are calculated as follows: Three Months Ended Nine Months Ended September 30, September 30, (In millions, except per share amounts) 2020 2019 2020 2019 Basic earnings (loss) (numerator): Net earnings (loss) $ 185.7 $ 189.8 $ 245.9 $ (3.7) Shares (denominator): Weighted average ordinary shares outstanding 516.9 516.0 516.8 515.5 Basic earnings (loss) per ordinary share $ 0.36 $ 0.37 $ 0.48 $ (0.01) Diluted earnings (loss) (numerator): Net earnings (loss) $ 185.7 $ 189.8 $ 245.9 $ (3.7) Shares (denominator): Weighted average ordinary shares outstanding 516.9 516.0 516.8 515.5 Share-based awards 0.8 0.2 0.5 — Total dilutive shares outstanding 517.7 516.2 517.3 515.5 Net earnings (loss) per diluted ordinary share $ 0.36 $ 0.37 $ 0.48 $ (0.01) Additional stock awards and restricted stock awards were outstanding during the three and nine months ended September 30, 2020 and 2019, but were not included in the computation of diluted earnings per ordinary share for each respective period because the effect would be anti-dilutive. Excluded shares at September 30, 2020 include certain share-based compensation awards whose performance conditions had not been fully met. Such excluded shares and anti-dilutive awards represented 8.8 million shares and 9.8 million shares for the three and nine months ended September 30, 2020, respectively, and 10.0 million shares and 9.9 million shares for the three and nine months ended September 30, 2019, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
Goodwill and Intangible Assets	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets The changes in the carrying amount of goodwill for the nine months ended September 30, 2020 are as follows: (In millions) North America Segment Europe Segment Rest of World Segment Total Balance at December 31, 2019: Goodwill $ 3,708.4 $ 4,548.6 $ 1,718.6 $ 9,975.6 Accumulated impairment losses (385.0) — — (385.0) 3,323.4 4,548.6 1,718.6 9,590.6 Foreign currency translation 33.8 197.5 (4.6) 226.7 $ 3,357.2 $ 4,746.1 $ 1,714.0 $ 9,817.3 Balance at September 30, 2020: Goodwill $ 3,742.2 $ 4,746.1 $ 1,714.0 $ 10,202.3 Accumulated impairment losses (385.0) — — (385.0) $ 3,357.2 $ 4,746.1 $ 1,714.0 $ 9,817.3 Intangible assets consist of the following components at September 30, 2020 and December 31, 2019: (In millions) Weighted Average Life (Years) Original Cost Accumulated Amortization Net Book Value September 30, 2020 Product rights, licenses and other (1) 15 $ 20,738.7 $ 9,890.1 $ 10,848.6 In-process research and development 117.2 — 117.2 $ 20,855.9 $ 9,890.1 $ 10,965.8 December 31, 2019 Product rights, licenses and other (1) 15 $ 20,109.1 $ 8,579.5 $ 11,529.6 In-process research and development 120.3 — 120.3 $ 20,229.4 $ 8,579.5 $ 11,649.9 ____________ (1) Represents amortizable intangible assets. Other intangible assets consists principally of customer lists and contractual rights. During the three and nine months ended September 30, 2019, the Company recognized impairment charges of $1.9 million and $71.8 million, respectively, which have been recorded as a component of amortization expense, primarily for the impairment of certain finite-lived and in-process research and development (“IPR&D”) assets acquired as part of the acquisition of the non-sterile, topicals-focused business of Renaissance Acquisition Holdings, LLC. No impairment charges were recognized during the three and nine months ended September 30, 2020. The impairment testing involved calculating the fair value of the assets based upon detailed valuations employing the income approach which utilized Level 3 inputs, as defined in Note 11 Financial Instruments and Risk Management . These valuations reflect, among other things, the impact of changes to the development programs, the projected development and regulatory time frames and the current competitive environment. Changes in any of the Company’s assumptions may result in a further reduction to the estimated fair values of these assets and could result in additional future impairment charges. The Company reviews goodwill for impairment annually on April 1st or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. As a result of the decline in the Company’s share price during the first quarter of 2020, and the general uncertainty and volatility in the economic environments in which the Company operates, including the impacts of the COVID-19 pandemic, the Company performed an interim goodwill impairment test as of March 31, 2020. The Company performed the annual goodwill impairment test as of April 1, 2020. There were no significant changes from the interim goodwill test performed at March 31, 2020 and the results were consistent with the interim goodwill impairment test. The Company has performed both the interim and annual goodwill impairment tests on a quantitative basis for its four reporting units, North America Generics, North America Brands, Europe and Rest of World. In estimating each reporting unit’s fair value, the Company performed an extensive valuation analysis, utilizing both income and market-based approaches, except for the North America Brands reporting unit where the fair value was estimated utilizing the income approach. The determination of the fair value of the reporting units requires the Company to make significant estimates and assumptions that affect the reporting unit’s expected future cash flows. These estimates and assumptions, utilizing Level 3 inputs, primarily include, but are not limited to, market multiples, control premiums, the discount rate, terminal growth rates, operating income before depreciation and amortization, and capital expenditures forecasts. As of March 31, 2020 and April 1, 2020, the allocation of the Company’s total goodwill was as follows: North America Generics $2.60 billion, North America Brands $0.65 billion, Europe $4.43 billion and Rest of World $1.65 billion. As of March 31, 2020 and April 1, 2020, the Company determined that the fair value of the North America Generics, North America Brands and Rest of World reporting units was substantially in excess of the respective unit’s carrying value . However, when compared to the April 1, 2019 test, the fair value of our overall business declined because of future forecasts and the decline in our share price. For the Europe reporting unit, the estimated fair value exceeded its carrying value by approximately $1.3 billion or 11.0% for both the interim and annual goodwill impairment test. The excess fair value for the Europe reporting unit is consistent with the result of the Company’s 2019 annual impairment test. As it relates to the income approach for the Europe reporting unit at March 31, 2020 and April 1, 2020, the Company forecasted cash flows for the next 5 years. During the forecast period, the revenue compound annual growth rate was approximately 7.5%. A terminal year value was calculated with a 2.0% revenue growth rate applied. The discount rate utilized was 11.0% and the estimated tax rate was 25.5%. Under the market-based approach, we utilized an estimated range of market multiples of 8.0 to 9.5 times EBITDA plus a control premium of 15.0%. If all other assumptions are held constant, a reduction in the terminal value growth rate by 3.5% or an increase in discount rate by 3.5% would result in an impairment charge for the Europe reporting unit. Due to the inherent uncertainty involved in making these estimates, actual results could differ from those estimates. In addition, changes in underlying assumptions, especially as it relates to the key assumptions detailed, could have a significant impact on the fair value of the reporting units. Amortization expense, which is classified primarily within cost of sales in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019 totaled: Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Intangible asset amortization expense $ 368.1 $ 405.6 $ 1,070.9 $ 1,210.3 IPR&D intangible asset impairment charges — — — 29.5 Finite-lived intangible asset impairment charges — 1.9 — 42.3 Total intangible asset amortization expense (including impairment charges) $ 368.1 $ 407.5 $ 1,070.9 $ 1,282.1 Intangible asset amortization expense over the remainder of 2020 and for the years ended December 31, 2021 through 2024 is estimated to be as follows (excludes the potential impact of the Combination): (In millions) 2020 $ 369 2021 1,404 2022 1,333 2023 1,166 2024 1,052

Financial Instruments and Risk

Financial Instruments and Risk Management	9 Months Ended
Financial Instruments and Risk Management	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments and Risk Management	Financial Instruments and Risk Management The Company is exposed to certain financial risks relating to its ongoing business operations. The primary financial risks that are managed by using derivative instruments are foreign currency risk and interest rate risk. Foreign Currency Risk Management In order to manage certain foreign currency risks, the Company enters into foreign exchange forward contracts to mitigate risk associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities. The foreign exchange forward contracts are measured at fair value and reported as current assets or current liabilities on the condensed consolidated balance sheets. Any gains or losses on the foreign exchange forward contracts are recognized in earnings in the period incurred in the condensed consolidated statements of operations. The Company has also entered into forward contracts to hedge forecasted foreign currency denominated sales from certain international subsidiaries. These contracts are designated as cash flow hedges to manage foreign currency transaction risk and are measured at fair value and reported as current assets or current liabilities on the condensed consolidated balance sheets. Any changes in the fair value of designated cash flow hedges are deferred in accumulated other comprehensive earnings (“AOCE”) and are reclassified into earnings when the hedged item impacts earnings. Net Investment Hedges The Company may hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries by either borrowing directly in foreign currencies and designating all or a portion of the foreign currency debt as a hedge of the applicable net investment position or entering into foreign currency swaps that are designated as hedges of net investments. The Company has designated certain Euro borrowings as a hedge of its investment in certain Euro-functional currency subsidiaries in order to manage foreign currency translation risk. Borrowings designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of AOCE until the sale or substantial liquidation of the underlying net investments. In addition, the Company manages the related foreign exchange risk of the Euro borrowings not designated as net investment hedges through certain Euro denominated financial assets and forward currency swaps. The following table summarizes the principal amounts of the Company’s outstanding Euro borrowings and the notional amounts of the Euro borrowings designated as net investment hedges: Notional Amount Designated as a Net Investment Hedge (in millions) Principal Amount September 30, December 31, 2.250% Euro Senior Notes due 2024 € 1,000.0 € 1,000.0 € 1,000.0 3.125% Euro Senior Notes due 2028 750.0 750.0 750.0 1.250% Euro Senior Notes due 2020 750.0 104.0 104.0 2.125% Euro Senior Notes due 2025 500.0 500.0 500.0 Total € 3,000.0 € 2,354.0 € 2,354.0 Interest Rate Risk Management The Company enters into interest rate swaps from time to time in order to manage interest rate risk associated with the Company’s fixed-rate and floating-rate debt. Interest rate swaps that meet specific accounting criteria are accounted for as fair value or cash flow hedges. All derivative instruments used to manage interest rate risk are measured at fair value and reported as current assets or current liabilities in the condensed consolidated balance sheets. For fair value hedges, the changes in the fair value of both the hedging instrument and the underlying debt obligations are included in interest expense. For cash flow hedges, the change in fair value of the hedging instrument is deferred through AOCE and is reclassified into earnings when the hedged item impacts earnings. Credit Risk Management The Company regularly reviews the creditworthiness of its financial counterparties and does not expect to incur a significant loss from the failure of any counterparties to perform under any agreements. The Company is not subject to any obligations to post collateral under derivative instrument contracts. Certain derivative instrument contracts entered into by the Company are governed by master agreements, which contain credit-risk-related contingent features that would allow the counterparties to terminate the contracts early and request immediate payment should the Company trigger an event of default on other specified borrowings. The Company records all derivative instruments on a gross basis in the condensed consolidated balance sheets. Accordingly, there are no offsetting amounts that net assets against liabilities. The Effect of Derivative Instruments in the Condensed Consolidated Balance Sheets Fair Values of Derivative Instruments Derivatives Designated as Hedging Instruments Asset Derivatives September 30, 2020 December 31, 2019 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Interest rate swaps Prepaid expenses and other current assets $ — Prepaid expenses and other current assets $ 22.3 Foreign currency forward contracts Prepaid expenses and other current assets 12.5 Prepaid expenses and other current assets 12.5 Total $ 12.5 $ 34.8 Liability Derivatives September 30, 2020 December 31, 2019 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Other current liabilities — Other current liabilities — Total $ — $ — The Effect of Derivative Instruments in the Condensed Consolidated Balance Sheets Fair Values of Derivative Instruments Derivatives Not Designated as Hedging Instruments Asset Derivatives September 30, 2020 December 31, 2019 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Prepaid expenses and other current assets $ 38.6 Prepaid expenses and other current assets $ 8.5 Total $ 38.6 $ 8.5 Liability Derivatives September 30, 2020 December 31, 2019 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Other current liabilities $ 17.1 Other current liabilities $ 12.9 Total $ 17.1 $ 12.9 The Effect of Derivative Instruments in the Condensed Consolidated Statement of Operations Derivatives in Fair Value Hedging Relationships Location of Gain (Loss) Amount of Gain (Loss) Recognized in Earnings on Derivatives (In millions) Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Interest rate swaps Interest expense $ — $ 3.3 $ 22.1 $ 24.3 Total $ — $ 3.3 $ 22.1 $ 24.3 Location of Gain (Loss) Amount of Gain (Loss) Recognized in Earnings on Hedged Items (In millions) Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 2023 Senior Notes (3.125% coupon) Interest expense $ — $ (3.3) $ (22.1) $ (24.3) Total $ — $ (3.3) $ (22.1) $ (24.3) In the first quarter of 2020, the Company terminated interest rate swaps designated as a fair value hedge resulting in net proceeds of approximately $45 million. The amount included in the above tables represents the fair value adjustment recognized at the date the interest rate swaps were settled. The Effect of Derivative Instruments in the Condensed Consolidated Statements of Comprehensive Earnings (Loss) Derivatives in Cash Flow Hedging Relationships Amount of Gain (Loss) Recognized in AOCE (Net of Tax) on Derivative Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Foreign currency forward contracts $ 29.5 $ (8.4) $ (0.5) $ 10.9 Total $ 29.5 $ (8.4) $ (0.5) $ 10.9 The Effect of Derivative Instruments in the Condensed Consolidated Statements of Comprehensive Earnings (Loss) Derivatives in Net Investment Hedging Relationships Amount of Gain (Loss) Recognized in AOCE Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Foreign currency borrowings and forward contracts $ (109.0) $ 106.2 $ (113.8) $ 126.9 Total $ (109.0) $ 106.2 $ (113.8) $ 126.9 The Effect of Derivative Instruments in the Condensed Consolidated Statement of Operations Derivatives in Cash Flow Hedging Relationships Location of Gain (Loss) Reclassified from AOCE into Earnings Amount of Gain (Loss) Reclassified from AOCE into Earnings Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Foreign currency forward contracts Net sales $ 5.1 $ 0.4 $ 2.3 $ (1.2) Interest rate swaps Interest expense (1.2) (1.8) (3.4) (5.4) Total $ 3.9 $ (1.4) $ (1.1) $ (6.6) At September 30, 2020, the Company expects that approximately $39.0 million of pre-tax net losses on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months. The Effect of Derivative Instruments in the Condensed Consolidated Statement of Operations Derivatives Not Designated as Hedging Instruments Location of Gain (Loss) Recognized in Earnings on Derivatives Amount of Gain (Loss) Recognized in Earnings on Derivatives Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Foreign currency option and forward contracts Other expense, net $ 9.8 $ 15.5 $ 22.9 $ (12.0) Total $ 9.8 $ 15.5 $ 22.9 $ (12.0) Fair Value Measurement Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: • Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. • Level 2: Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities. • Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value. Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above: September 30, 2020 (In millions) Level 1 Level 2 Level 3 Total Recurring fair value measurements Financial Assets Cash equivalents: Money market funds $ 0.9 $ — $ — $ 0.9 Total cash equivalents 0.9 — — 0.9 Equity securities: Exchange traded funds 40.2 — — 40.2 Marketable securities 0.7 — — 0.7 Total equity securities 40.9 — — 40.9 Available-for-sale fixed income investments: Corporate bonds — 19.4 — 19.4 U.S. Treasuries — 12.8 — 12.8 Agency mortgage-backed securities — 1.8 — 1.8 Asset backed securities — 4.5 — 4.5 Other — 0.6 — 0.6 Total available-for-sale fixed income investments — 39.1 — 39.1 Foreign exchange derivative assets — 51.1 — 51.1 Total assets at recurring fair value measurement $ 41.8 $ 90.2 $ — $ 132.0 Financial Liabilities Foreign exchange derivative liabilities — 17.1 — 17.1 Contingent consideration — — 213.2 213.2 Total liabilities at recurring fair value measurement $ — $ 17.1 $ 213.2 $ 230.3 December 31, 2019 (In millions) Level 1 Level 2 Level 3 Total Recurring fair value measurements Financial Assets Cash equivalents: Money market funds $ 0.7 $ — $ — $ 0.7 Total cash equivalents 0.7 — — 0.7 Equity securities: Exchange traded funds 38.3 — — 38.3 Marketable securities 0.7 — — 0.7 Total equity securities 39.0 — — 39.0 Available-for-sale fixed income investments: Corporate bonds — 10.8 — 10.8 U.S. Treasuries — 9.5 — 9.5 Agency mortgage-backed securities — 2.3 — 2.3 Asset backed securities — 3.6 — 3.6 Other — 0.6 — 0.6 Total available-for-sale fixed income investments — 26.8 — 26.8 Foreign exchange derivative assets — 21.0 — 21.0 Interest rate swap derivative assets — 22.3 — 22.3 Total assets at recurring fair value measurement $ 39.7 $ 70.1 $ — $ 109.8 Financial Liabilities Foreign exchange derivative liabilities $ — $ 12.9 $ — $ 12.9 Contingent consideration — — 250.7 250.7 Total liabilities at recurring fair value measurement $ — $ 12.9 $ 250.7 $ 263.6 For financial assets and liabilities that utilize Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including the LIBOR yield curve, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities: • Cash equivalents — valued at observable net asset value prices. • Equity securities, exchange traded funds — valued at the active quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the condensed consolidated statements of operations. • Equity securities, marketable securities — valued using quoted stock prices from public exchanges at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the condensed consolidated statements of operations. • Available-for-sale fixed income investments — valued at the quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value, net of income taxes, are included in accumulated other comprehensive loss as a component of shareholders’ equity. • Interest rate swap derivative assets and liabilities — valued using the LIBOR/EURIBOR yield curves at the reporting date. Counterparties to these contracts are highly rated financial institutions. • Foreign exchange derivative assets and liabilities — valued using quoted forward foreign exchange prices and spot rates at the reporting date. Counterparties to these contracts are highly rated financial institutions. Contingent Consideration The fair value measurement of contingent consideration is determined using Level 3 inputs. The Company’s contingent consideration represents a component of the total purchase consideration for Pfizer’s proprietary dry powder inhaler delivery platform and certain other acquisitions. The measurement is calculated using unobservable inputs based on the Company’s own assumptions primarily related to probability and timing of future development and commercial milestones and future profit sharing payments which are discounted using a market rate of return. At September 30, 2020 and December 31, 2019, discount rates ranging from 3.5% to 10.5% were utilized in the valuations. Significant changes in unobservable inputs could result in material changes to the contingent consideration liability. A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2019 to September 30, 2020 is as follows: (In millions) Current Portion (1) Long-Term Portion (2) Total Contingent Consideration Balance at December 31, 2019 $ 120.4 $ 130.3 $ 250.7 Payments (82.1) — (82.1) Reclassifications 52.7 (52.7) — Accretion — 9.0 9.0 Fair value loss (3) 33.8 1.8 35.6 Balance at September 30, 2020 $ 124.8 $ 88.4 $ 213.2 ____________ (1) Included in other current liabilities in the condensed consolidated balance sheets. (2) Included in other long-term obligations in the condensed consolidated balance sheets. (3) Included in litigation settlements and other contingencies, net in the condensed consolidated statements of operations. Although the Company has not elected the fair value option for other financial assets and liabilities, any future transacted financial asset or liability will be evaluated for the fair value election.

Debt

Debt	9 Months Ended
Debt	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt	Debt Short-Term Borrowings The Company had no short-term borrowings as of September 30, 2020 and December 31, 2019. The following provides an overview of the Company’s short-term credit facilities. Receivables Facility and Note Securitization Facility The Company has the $400 million Receivables Facility which expires in April 2022. The Company also has the $200 million Note Securitization Facility which expires on August 30, 2021. Borrowings outstanding under the Receivables Facility bear interest at a commercial paper rate plus 0.925% and under the Note Securitization Facility at a rate per annum quoted from time to time by MUFG Bank, Ltd. plus 1.00% and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as a component of accounts receivable, net, in our condensed consolidated balance sheets. In addition, the agreements governing the Receivables Facility and Note Securitization Facility contain various customary affirmative and negative covenants, and customary default and termination provisions with which the Company was compliant as of September 30, 2020. As of September 30, 2020, the Company had no amounts outstanding under the Receivables Facility or the Note Securitization Facility. Commercial Paper Program The Company maintains a $1.65 billion commercial paper program (the “Commercial Paper Program”) to support its working capital requirements and for general corporate purposes. There were no commercial paper notes (the “CP Notes”) outstanding under this program as of September 30, 2020 and December 31, 2019. Amounts available under the Commercial Paper Program may be borrowed, repaid and re-borrowed from time to time, with the aggregate principal amount of the CP Notes outstanding under the Commercial Paper Program at any time not to exceed $1.65 billion. The Company’s Revolving Credit Facility (as defined below) will be available to pay the CP Notes, if necessary. The maturities of the CP Notes will vary but will not exceed 364 days from the date of issue. The Commercial Paper Program will terminate upon the consummation of the Combination. We expect that Viatris will establish a commercial paper program on substantially similar terms following the consummation of the Combination. Long-Term Debt A summary of long-term debt is as follows: (In millions) Interest Rate as of September 30, 2020 September 30, December 31, Current portion of long-term debt: 2020 Floating Rate Euro Notes (a) — 560.6 2020 Euro Senior Notes 1.250 % 878.9 840.1 2020 Senior Notes 3.750 % 50.0 50.0 2021 Senior Notes 3.150 % 2,249.6 — Other 6.5 8.3 Deferred financing fees (2.4) (1.4) Current portion of long-term debt $ 3,182.6 $ 1,457.6 Non-current portion of long-term debt: 2021 Senior Notes ** 3.150 % — 2,249.2 2023 Senior Notes (b) * 3.125 % 785.4 771.8 2023 Senior Notes * 4.200 % 499.3 499.1 2024 Euro Senior Notes ** 2.250 % 1,170.4 1,119.3 2025 Euro Senior Notes * 2.125 % 585.1 559.6 2026 Senior Notes 3.950 % 2,239.3 2,238.1 2028 Euro Senior Notes 3.125 % 872.7 834.3 2028 Senior Notes * 4.550 % 748.5 748.4 2043 Senior Notes * 5.400 % 497.3 497.2 2046 Senior Notes ** 5.250 % 999.9 999.8 2048 Senior Notes * 5.200 % 747.7 747.7 Other 5.5 8.9 Deferred financing fees (49.6) (59.1) Long-term debt $ 9,101.5 $ 11,214.3 ____________ (a) The 2020 Floating Rate Euro Notes were repaid at maturity in the second quarter of 2020. The instrument bore interest at a rate of three-month EURIBOR plus 0.50% per annum, reset quarterly. (b) In the first quarter of 2020, the Company terminated interest rate swaps designated as a fair value hedge resulting in net proceeds of approximately $45 million. The fair value adjustment will be amortized to interest expense over the remaining term of the notes. * Instrument was issued by Mylan Inc. ** Instrument was issued by Mylan N.V. For additional information, see Note 10 Debt in Mylan N.V.’s 2019 Form 10-K. Revolving Credit Facility The Company has a $2.0 billion revolving credit facility which is scheduled to expire in July 2023 (the “Revolving Credit Facility”). The Revolving Credit Facility contains a maximum consolidated leverage ratio financial covenant requiring maintenance of a maximum ratio of 3.75 to 1.00 for consolidated total indebtedness as of the end of any quarter to consolidated EBITDA for the trailing four quarters as defined in the related credit agreements (“maximum leverage ratio”). On June 16, 2020, the Company entered into an amendment to the Revolving Credit Facility to temporarily increase the maximum leverage ratio to 4.25 to 1.00 after the March 31, 2020 reporting period through the December 31, 2020 reporting period with a maximum leverage ratio of 3.75 to 1.00 thereafter. The Company is in compliance at September 30, 2020 and expects to remain in compliance for the next twelve months. The Revolving Credit Facility will terminate upon completion of the Combination. Fair Value At September 30, 2020 and December 31, 2019, the aggregate fair value of the Company’s outstanding notes was approximately $13.7 billion and $13.4 billion, respectively. The fair values of the outstanding notes were valued at quoted market prices from broker or dealer quotations and were classified as Level 2 in the fair value hierarchy. Mandatory minimum repayments remaining on the notional amount of outstanding long-term debt at September 30, 2020 were as follows for each of the periods ending December 31: (In millions) Total 2020 $ 929 2021 2,250 2022 — 2023 1,250 2024 1,172 Thereafter 6,715 Total $ 12,316

Comprehensive Earnings

Comprehensive Earnings	9 Months Ended
Comprehensive Earnings	Sep. 30, 2020
Equity [Abstract]
Comprehensive Earnings	Comprehensive Loss Accumulated other comprehensive loss, as reflected on the condensed consolidated balance sheets, is comprised of the following: (In millions) September 30, December 31, Accumulated other comprehensive loss: Net unrealized gain on marketable securities, net of tax $ 1.4 $ 0.6 Net unrecognized loss and prior service cost related to defined benefit plans, net of tax (14.5) (17.4) Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax (31.3) (31.6) Net unrecognized loss on derivatives in net investment hedging relationships, net of tax (188.0) (74.3) Foreign currency translation adjustment (1,191.4) (1,674.5) $ (1,423.8) $ (1,797.2) Components of accumulated other comprehensive loss, before tax, consist of the following, for the three and nine months ended September 30, 2020 and 2019: Three Months Ended September 30, 2020 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at June 30, 2020, net of tax $ (55.7) $ (79.0) $ 1.3 $ (12.4) $ (1,879.1) $ (2,024.9) Other comprehensive earnings (loss) before reclassifications, before tax 36.4 (114.7) — (1.7) 687.7 607.7 Amounts reclassified from accumulated other comprehensive earnings (loss), before tax: Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales (5.1) (5.1) (5.1) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 1.2 1.2 1.2 Amortization of actuarial loss included in SG&A 0.1 0.1 Net other comprehensive earnings (loss), before tax 32.5 (114.7) — (1.6) 687.7 603.9 Income tax provision (benefit) 8.1 (5.7) (0.1) 0.5 — 2.8 Balance at September 30, 2020, net of tax $ (31.3) $ (188.0) $ 1.4 $ (14.5) $ (1,191.4) $ (1,423.8) Three Months Ended September 30, 2019 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at June 30, 2019, net of tax $ (33.0) $ (110.2) $ 0.7 $ 1.7 $ (1,400.9) $ (1,541.7) Other comprehensive earnings (loss) before reclassifications, before tax (12.0) 111.8 0.1 (0.8) (748.9) (649.8) Amounts reclassified from accumulated other comprehensive loss, before tax: Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales (0.4) (0.4) (0.4) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 1.8 1.8 1.8 Amortization of prior service costs included in SG&A 0.3 0.3 Amortization of actuarial loss included in SG&A (0.2) (0.2) Net other comprehensive earnings (loss), before tax (10.6) 111.8 0.1 (0.7) (748.9) (648.3) Income tax provision (benefit) (4.0) 5.5 — (0.3) — 1.2 Balance at September 30, 2019, net of tax $ (39.6) $ (3.9) $ 0.8 $ 1.3 $ (2,149.8) $ (2,191.2) Nine Months Ended September 30, 2020 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2019, net of tax $ (31.6) $ (74.3) $ 0.6 $ (17.4) $ (1,674.5) $ (1,797.2) Other comprehensive (loss) earnings before reclassifications, before tax (1.3) (119.7) 0.8 3.0 483.1 365.9 Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax: Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales (2.3) (2.3) (2.3) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 3.4 3.4 3.4 Amortization of actuarial loss included in SG&A 0.4 0.4 Net other comprehensive (loss) earnings, before tax (0.2) (119.7) 0.8 3.4 483.1 367.4 Income tax (benefit) provision (0.5) (6.0) — 0.5 — (6.0) Balance at September 30, 2020, net of tax $ (31.3) $ (188.0) $ 1.4 $ (14.5) $ (1,191.4) $ (1,423.8) Nine Months Ended September 30, 2019 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2018, net of tax $ (53.1) $ (130.9) $ — $ 1.7 $ (1,259.0) $ (1,441.3) Other comprehensive earnings (loss) before reclassifications, before tax 18.2 133.6 0.7 (0.7) (890.8) (739.0) Amounts reclassified from accumulated other comprehensive loss, before tax: Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales 1.2 1.2 1.2 Loss on interest rate swaps classified as cash flow hedges, included in interest expense 5.4 5.4 5.4 Amortization of prior service costs included in SG&A 0.8 0.8 Amortization of actuarial loss included in SG&A (0.6) (0.6) Net other comprehensive earnings (loss), before tax 24.8 133.6 0.7 (0.5) (890.8) (732.2) Income tax provision (benefit) 7.9 6.6 (0.1) (0.3) — 14.1 Cumulative effect of the adoption of new accounting standards (3.4) — — (0.2) — (3.6) Balance at September 30, 2019, net of tax $ (39.6) $ (3.9) $ 0.8 $ 1.3 $ (2,149.8) $ (2,191.2)

Segment Information

Segment Information	9 Months Ended
Segment Information	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Information	Segment Information Mylan reports segment information on a geographic basis. This approach reflects the company’s focus on bringing its broad and diversified portfolio of generic, branded generic, brand-name and over-the-counter products to people in markets everywhere. Our North America segment comprises our operations in the U.S. and Canada. Our Europe segment encompasses our operations in 35 countries, including France, Italy, Germany, the United Kingdom (“U.K.”) and Spain. Our Rest of World segment reflects our operations in more than 120 countries, including Japan, Australia, China, Brazil, Russia, India, South Africa and certain markets in the Middle East and Southeast Asia. The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability. Segment profitability represents segment gross profit less direct research and development (“R&D”) and direct SG&A. Certain general and administrative and R&D expenses not allocated to the segments, including certain special items, net charges for litigation settlements and other contingencies, amortization of intangible assets, impairment charges and other expenses not directly attributable to the segments are reported separately or outside of segment profitability. Items below the earnings from operations line on the Company’s condensed consolidated statements of operations are not presented by segment, since they are excluded from the measure of segment profitability. The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker. The accounting policies of the segments are the same as those described in Note 2 Summary of Significant Accounting Policies included in the 2019 Form 10-K, and Note 3 Recent Accounting Pronouncements, Adoption of New Accounting Standards included in this Form 10-Q. Intersegment revenues are accounted for at current market values and are eliminated at the consolidated level. Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information. (In millions) North America Europe Rest of World Eliminations Consolidated Three Months Ended September 30, 2020 Net sales $ 1,028.8 $ 1,123.8 $ 795.5 $ — $ 2,948.1 Other revenue 17.4 3.4 3.2 — 24.0 Intersegment revenue 39.3 23.6 126.6 (189.5) — Total $ 1,085.5 $ 1,150.8 $ 925.3 $ (189.5) $ 2,972.1 Segment profitability $ 497.9 $ 348.1 $ 120.3 $ — $ 966.3 Intangible asset amortization expense (368.1) Globally managed research and development costs (31.0) Corporate costs and special items (196.9) Litigation settlements & other contingencies (18.9) Earnings from operations $ 351.4 Nine Months Ended September 30, 2020 Net sales $ 3,023.3 $ 3,080.7 $ 2,128.2 $ — $ 8,232.2 Other revenue 51.8 11.1 27.4 — 90.3 Intersegment revenue 133.4 83.2 387.9 (604.5) — Total $ 3,208.5 $ 3,175.0 $ 2,543.5 $ (604.5) $ 8,322.5 Segment profitability $ 1,447.5 $ 873.2 $ 321.6 $ — $ 2,642.3 Intangible asset amortization expense (1,070.9) Globally managed research and development costs (121.0) Corporate costs and special items (743.6) Litigation settlements & other contingencies (36.5) Earnings from operations $ 670.3 (In millions) North America Europe Rest of World Eliminations Consolidated Three Months Ended September 30, 2019 Net sales $ 1,088.6 $ 1,045.9 $ 793.7 $ — $ 2,928.2 Other revenue 17.6 3.8 12.1 — 33.5 Intersegment revenue 13.9 23.2 134.0 (171.1) — Total $ 1,120.1 $ 1,072.9 $ 939.8 $ (171.1) $ 2,961.7 Segment profitability $ 489.9 $ 325.1 $ 170.3 $ — $ 985.3 Intangible asset amortization expense (405.6) Intangible asset impairment charges (1.9) Globally managed research and development costs (47.3) Corporate costs and special items (258.7) Litigation settlements & other contingencies 51.9 Earnings from operations $ 323.7 Nine Months Ended September 30, 2019 Net sales $ 3,035.0 $ 2,930.7 $ 2,241.3 $ — $ 8,207.0 Other revenue 58.8 12.3 30.6 — 101.7 Intersegment revenue 64.6 66.3 382.1 (513.0) — Total $ 3,158.4 $ 3,009.3 $ 2,654.0 $ (513.0) $ 8,308.7 Segment profitability $ 1,342.3 $ 723.7 $ 435.2 $ — $ 2,501.2 Intangible asset amortization expense (1,210.3) Intangible asset impairment charges (71.8) Globally managed research and development costs (167.8) Corporate costs and special items (638.4) Litigation settlements & other contingencies 30.3 Earnings from operations $ 443.2

Restructuring

Restructuring	9 Months Ended
Restructuring	Sep. 30, 2020
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring 2020 Restructuring Program On February 27, 2020, the Company announced that it has formalized the next steps in its efforts to sustain long-term value creation through the proactive transformation of its business. This transformation initiative includes a new global restructuring program. The program is intended to support the Company’s effort to improve operating performance and meet anticipated market demands by ensuring that the Company is appropriately structured and resourced to deliver sustainable value to customers, patients, other stakeholders and shareholders. Key activities under the program include supply chain network optimization intended to maximize the efficiency of the Company’s global manufacturing and distribution network capacity and further optimizing functional capabilities that support business growth. The Company is currently developing the details of the initiatives, including workforce actions and other restructuring activities. Further details will be disclosed as plans are finalized, including the estimated amount or range of amounts to be incurred by major cost type and future cash expenditures associated with those initiatives. As a result of the COVID-19 pandemic and the related uncertainty and complexity of the current environment, the Company has delayed the implementation of the 2020 restructuring program. 2016 Restructuring Program On December 5, 2016, the Company announced a restructuring program representing a series of actions in certain locations that are anticipated to further streamline its operations globally. Since 2015, the Company has made a number of significant acquisitions, and as part of the holistic, global integration of these acquisitions, the Company is focused on how to best optimize and maximize all of its assets across the organization and across all geographies. Charges for restructuring and ongoing cost reduction initiatives are recorded in the period the Company commits to a restructuring or cost reduction plan, or executes specific actions contemplated by the plan and all criteria for liability recognition have been met. During the second quarter of 2018, the Company commenced comprehensive restructuring and remediation activities, which are aimed at reducing the complexity at the Morgantown, West Virginia plant and include the discontinuation and transfer to other manufacturing sites of a number of products, a reduction of the workforce and extensive process and facility remediation. The restructuring actions other than for this plant are substantially complete. At this time, the total expenses related to the additional restructuring and remediation activities at the Morgantown plant cannot be reasonably estimated. The following table summarizes the restructuring charges and the reserve activity from December 31, 2019 to September 30, 2020: (In millions) Employee Related Costs Other Exit Costs Total Balance at December 31, 2019: $ 26.4 $ 2.8 $ 29.2 Charges (1) 2.9 4.7 7.6 Cash payment (6.0) (0.9) (6.9) Utilization — (3.7) (3.7) Foreign currency translation (0.4) (0.1) (0.5) Balance at March 31, 2020: $ 22.9 $ 2.8 $ 25.7 Charges (1) 0.4 23.2 23.6 Cash payment (3.8) (3.2) (7.0) Utilization — (20.0) (20.0) Foreign currency translation 0.4 0.1 0.5 Balance at June 30, 2020: $ 19.9 $ 2.9 $ 22.8 Charges (1) 4.7 9.8 14.5 Cash payment (3.6) (2.2) (5.8) Utilization — (7.5) (7.5) Foreign currency translation — — — Balance at September 30, 2020: $ 21.0 $ 3.0 $ 24.0 ____________ (1) For the three months ended September 30, 2020, total restructuring charges in North America, Europe and Rest of World were approximately $11.9 million, $2.3 million and $0.3 million, respectively. For the nine months ended September 30, 2020, total restructuring charges in North America, Europe, Rest of World, and corporate were approximately $19.9 million, $23.7 million, $1.6 million, and $0.5 million, respectively. At September 30, 2020 and December 31, 2019, accrued liabilities for restructuring and other cost reduction programs were primarily included in other current liabilities in the condensed consolidated balance sheets.

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes CARES Act On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted and signed into law. The CARES Act includes several provisions, including increasing the amount of deductible interest, allowing companies to carryback certain Net Operating Losses (“NOLs”) and increasing the amount of NOLs that corporations can use to offset income. We anticipate that the applicable provisions of the CARES Act will reduce our 2020 income tax expense by approximately $27.0 million, of which $16.5 million has been recorded as of September 30, 2020. We will continue to monitor and assess the impact the CARES Act may have on our business and financial results. Tax Examinations The Company is subject to income taxes and tax audits in many jurisdictions. A certain degree of estimation is thus required in recording the assets and liabilities related to income taxes. Tax audits and examinations can involve complex issues, interpretations, and judgments and the resolution of matters that may span multiple years, particularly if subject to litigation or negotiation. Although the Company believes that adequate provisions have been made for these uncertain tax positions, the Company’s assessment of uncertain tax positions is based on estimates and assumptions that the Company believes are reasonable but the estimates for unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variations from such estimates could materially affect the Company’s financial condition, results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire. Mylan is subject to ongoing IRS examinations. The years 2015 through 2018 are open years under examination. The years 2012, 2013 and 2014 have one matter open, and a Tax Court petition has been filed regarding the matter and a trial was held in December 2018 and is discussed further below. During the second quarter of 2019, we reached an agreement in principle with the IRS to resolve all issues relating to our positions on the February 27, 2015 acquisition by Mylan N.V. of Mylan Inc. and Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business. Under the agreement in principle, which was finalized as part of a closing agreement with the IRS on October 11, 2019, our status as a non-U.S. corporation for U.S. Federal income tax purposes has been confirmed, and we have adjusted the interest rates used for intercompany loans. During the second quarter of 2019, the Company recorded a reserve of approximately $140.0 million as part of its liability for uncertain tax positions, with a net impact to the income tax provision of approximately $129.9 million related to this matter. Once the agreement with the IRS was finalized in the fourth quarter of 2019, the Company increased the reserve by $15.0 million with a corresponding increase to the income tax provision. Several international audits are currently in progress. In some cases, the tax auditors have proposed adjustments to our tax positions including with respect to intercompany transactions, and we are in ongoing discussions with the auditors regarding the validity of their positions. The Company has recorded a reserve for uncertain tax positions of $126.9 million and $89.2 million, including interest and penalties, in connection with its international audits at September 30, 2020 and December 31, 2019, respectively. In certain cases, these audits can also result in non-tax consequences. For example, under French law, certain tax matters are automatically referred for criminal investigation. The Company’s major state taxing jurisdictions remain open from fiscal year 2013 through 2019, with several state audits currently in progress. The Company’s major international taxing jurisdictions remain open from 2012 through 2019, some of which are indemnified by Strides Arcolab Limited (“Strides Arcolab”) for tax assessments. Tax Court Proceedings The Company's U.S. federal income tax returns for 2012 through 2014 had been subject to proceedings in U.S. Tax Court involving a dispute with the IRS regarding whether certain costs related to abbreviated new drug applications were eligible to be expensed and deducted immediately or required to be amortized over longer periods. A trial was held in U.S. Tax Court in December 2018. Both parties delivered their final post-trial briefs on June 27, 2019 and are awaiting the court’s final decision. Accounting for Uncertainty in Income Taxes The impact of an uncertain tax position that is more likely than not of being sustained upon audit by the relevant taxing authority must be recognized at the largest amount that is more likely than not to be sustained. No portion of an uncertain tax position will be recognized if the position has less than a 50% likelihood of being sustained.

Litigation

Litigation	9 Months Ended
Litigation	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Litigation The Company is involved in various disputes, governmental and/or regulatory inquiries, investigations and proceedings, tax proceedings and litigation matters, both in the U.S. and abroad, that arise from time to time, some of which could result in losses, including damages, fines and/or civil penalties, and/or criminal charges against the Company. These matters are often complex and have outcomes that are difficult to predict. The Company is also party to certain proceedings and litigation matters for which it may be entitled to indemnification under the respective sale and purchase agreements relating to the acquisitions of the former Merck Generics business, Agila Specialties Private Limited, Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business, and certain other acquisitions. While the Company believes that it has meritorious defenses with respect to the claims asserted against it and intends to vigorously defend its position, the process of resolving these matters is inherently uncertain and may develop over a long period of time, and so it is not possible to predict the ultimate resolution of any such matter. It is possible that an unfavorable resolution of any of the ongoing matters or the inability or denial of Merck KGaA, Strides Arcolab, Abbott Laboratories, or another indemnitor or insurer to pay an indemnified claim, could have a material adverse effect on the Company’s business, financial condition, results of operations, cash flows and/or ordinary share price. Some of these governmental inquiries, investigations, proceedings and litigation matters with which the Company is involved are described below, and unless otherwise disclosed, the Company is unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. The Company records accruals for loss contingencies to the extent we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company is also involved in other pending proceedings for which, in the opinion of the Company based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s business, financial position, results of operations, cash flows and/or ordinary share price. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in the opinion of the Company, become material, the Company will disclose such matters. Legal costs are recorded as incurred and are classified in SG&A in the Company’s condensed consolidated statements of operations. Modafinil Antitrust Litigation Beginning in April 2006, Mylan and four other drug manufacturers were named as defendants in civil lawsuits filed in or transferred to the U.S. District Court for the Eastern District of Pennsylvania (“EDPA”) by a variety of plaintiffs purportedly representing direct and indirect purchasers of the drug modafinil and in a lawsuit filed by Apotex, Inc., a manufacturer of generic drugs. These actions alleged violations of federal antitrust and state laws in connection with the generic defendants’ settlement of patent litigation with Cephalon relating to modafinil. Mylan has settled all of these lawsuits. The Company recorded approximately $18.0 million of expense related to this matter in the second quarter of 2019, which was subsequently paid during the year ended December 31, 2019. At December 31, 2019, the Company had a total accrual of approximately $14.4 million related to this matter, which is included in other current liabilities in the condensed consolidated balance sheets. The amount accrued was paid during 2020. On July 10, 2015, the Louisiana Attorney General filed a lawsuit in the 19th Judicial District Court in Louisiana against Mylan and three other drug manufacturers asserting state law claims based on the same underlying allegations as those made in the litigation then pending in the EDPA. On December 8, 2016, the District Court dismissed the lawsuit with prejudice, which the State of Louisiana appealed. The appeals court subsequently remanded the lawsuit to the District Court to include certain language in order to make the District Court’s dismissal decision final and appealable. The Company believes that it has strong defenses to the remaining case. Although it is reasonably possible that the Company may incur additional losses from this matter, any amount cannot be reasonably estimated at this time. Pioglitazone Beginning in December 2013, Mylan, Takeda, and several other drug manufacturers were named as defendants in civil lawsuits consolidated in the U.S. District Court for the Southern District of New York (“SDNY”) by plaintiffs which purport to represent direct and indirect purchasers of branded or generic Actos® and Actoplus Met®. These actions allege violations of state and federal competition laws in connection with the defendants’ settlements of patent litigation in 2010 related to Actos® and Actoplus Met®. Mylan’s motion to dismiss the indirect purchasers’ complaint was granted and no appeal was filed as to Mylan. Following the appellate decision relating to other defendants, the direct purchasers filed an amended complaint against Mylan and the other manufacturers. Mylan’s motion to dismiss was granted with prejudice on October 8, 2019. Trade Agreements Act (“TAA”) On April 9, 2018, a subsidiary of Mylan N.V. received a civil investigative demand from the Commercial Litigation Branch of the U.S. Department of Justice (“DOJ”) concerning its TAA compliance for certain products. The company fully cooperated with DOJ. On September 14, 2018, the United States District Court for the Southern District of Ohio unsealed a qui tam lawsuit filed against the Mylan N.V. subsidiary concerning its TAA compliance for the same products identified in DOJ’s civil investigative demand. DOJ declined to intervene in the lawsuit and has closed its investigation. Plaintiffs filed a Notice of Voluntary Dismissal of Mylan, which the Court granted on October 13, 2020 and dismissed the case against Mylan. EpiPen® Auto-Injector Department of Veterans Affairs Request for Information On June 30, 2017, the Company responded to a request for information from the Department of Veterans Affairs (“VA”) (acting on behalf of itself and other government agencies) requesting certain historical pricing data related to the EpiPen® Auto-Injector. The Company and the VA have been engaged in a continuing dialogue regarding the classification of the EpiPen® Auto-Injector as a covered drug under Section 603 of the Veterans Health Care Act of 1992, Public Law 102-585. The Company historically classified EpiPen® Auto-Injector as a non-covered drug with the VA based upon long standing written guidance from the federal government. The Company has voluntarily reclassified the EpiPen® Auto-Injector as a covered drug, effective from April 1, 2017. The Company is fully cooperating with the VA. EpiPen® Auto-Injector Civil Litigation Mylan Specialty and other Mylan-affiliated entities have been named as defendants in putative indirect purchaser class actions relating to the pricing and/or marketing of the EpiPen® Auto-Injector. The plaintiffs in these cases assert violations of various federal and state antitrust and consumer protection laws, the Racketeer Influenced and Corrupt Organizations Act (“RICO”), as well as common law claims. Plaintiffs’ claims include purported challenges to the prices charged for the EpiPen® Auto-Injector and/or the marketing of the product in packages containing two auto-injectors, as well as allegedly anti-competitive conduct. A Mylan officer and other non-Mylan affiliated companies were also named as defendants in some of the class actions. These lawsuits were filed in the various federal and state courts and have either been dismissed or transferred into a multidistrict litigation (“MDL”) in the U.S. District Court for the District of Kansas and have been consolidated. Mylan filed a motion to dismiss the consolidated amended complaint, which was granted in part and denied in part. On December 7, 2018, the plaintiffs filed a motion for class certification. On February 27, 2020, the District Court issued an order denying in part and granting in part plaintiffs’ motion for class certification. The District Court declined to certify consumer protection and unjust enrichment damages classes, as well as an injunctive relief class. The District Court certified an antitrust class that applies to 17 states and a RICO class. We filed a petition for permission to appeal the class certification decision on March 12, 2020, which was denied. On July 15, 2020, Defendants filed a motion for summary judgment as to the remaining claims asserted by plaintiffs. The motion is pending. A trial date has been scheduled for April 2021. We believe that the remaining claims in these lawsuits are without merit and intend to defend against them vigorously. On February 14, 2020, Mylan Specialty and other Mylan-affiliated entities, together with other non-Mylan affiliated companies, were named as defendants in a putative direct purchaser class action filed in the U.S. District Court for the District of Kansas relating to the pricing and/or marketing of the EpiPen® Auto-Injector. The plaintiff in this case asserts federal antitrust claims which are based on allegations that are similar to those in the putative indirect purchaser class actions discussed above. On June 18, 2020, the District Court granted Mylan’s motion to compel pre-suit mediation, which did not result in a resolution of this matter. On September 10, 2020, the plaintiff filed an amended complaint. Mylan filed a motion to dismiss the amended complaint on October 13, 2020. On November 3, 2020, the plaintiff filed a second amended complaint that is substantially similar to the allegations in the amended complaint thereby mooting the motion to dismiss.We believe that the claims in this lawsuit are without merit and intend to defend against them vigorously. Beginning in March 2020, Mylan Inc. and Mylan Specialty, together with other non-Mylan affiliated companies, were named as defendants in putative direct purchaser class actions filed in the U.S. District Court for the District of Minnesota relating to contracts with certain pharmacy benefit managers concerning EpiPen® Auto-Injector. The plaintiffs claim that the alleged conduct resulted in the exclusion or restriction of competing products and the elimination of pricing constraints in violation of RICO and federal antitrust law. These actions have been consolidated and, on August 21, 2020, Defendants filed a motion to dismiss, which remains pending. We believe that the claims in these lawsuits are without merit and intend to defend against them vigorously. On April 24, 2017, Sanofi-Aventis U.S., LLC (“Sanofi”) filed a lawsuit against Mylan Inc. and Mylan Specialty in the U.S. District Court for the District of New Jersey. This lawsuit has been transferred into the aforementioned MDL. In this lawsuit, Sanofi alleges exclusive dealings and anti-competitive marketing practices in violation of the antitrust laws in connection with the sale and marketing of the EpiPen® Auto-Injector. On November 1, 2018, Sanofi filed a Motion for a Suggestion of Remand of the case to the U.S. District Court for the District of New Jersey. On January 23, 2019, the Court denied Sanofi’s motion without prejudice. On June 28, 2019, Mylan filed a motion for summary judgment as to the claims asserted by Sanofi and Sanofi filed both a motion for partial summary judgment with respect to its claims against Mylan and for summary judgment with respect to Mylan’s counterclaims. These motions remain pending. We believe that Sanofi’s claims in this lawsuit are without merit and intend to defend against them vigorously. The Company has a total accrual of approximately $10.0 million related to this matter at September 30, 2020, which is included in other current liabilities in the condensed consolidated balance sheets. The Company believes that it has strong defenses to current and future potential civil litigation, as well as governmental investigations, discussed in this “EpiPen® Auto-Injector” section of this Note 18 Litigation . Although it is reasonably possible that the Company may incur additional losses from these matters, any amount cannot be reasonably estimated at this time. In addition, the Company expects to incur additional legal and other professional service expenses associated with such matters in future periods and will recognize these expenses as services are received. The Company believes that the ultimate amount paid for these services and claims could have a material effect on the Company's business, financial condition, results of operations, cash flows and/or ordinary share price in future periods. Drug Pricing Matters Department of Justice On December 3, 2015, a subsidiary of Mylan N.V. received a subpoena from the Antitrust Division of the DOJ seeking information relating to the marketing, pricing, and sale of our generic Doxycycline products and any communications with competitors about such products. On September 8, 2016, a subsidiary of Mylan N.V., as well as certain employees and a member of senior management, received subpoenas from the DOJ seeking additional information relating to the marketing, pricing and sale of our generic Cidofovir, Glipizide-metformin, Propranolol and Verapamil products and any communications with competitors about such products. Related search warrants also were executed. On May 10, 2018, a subsidiary of Mylan N.V. received a civil investigative demand from the Civil Division of the DOJ seeking information relating to the pricing and sale of its generic drug products. The Company is fully cooperating with the DOJ. Civil Litigation Beginning in 2016, the Company, along with other manufacturers, has been named as a defendant in lawsuits generally alleging anticompetitive conduct with respect to generic drugs. The lawsuits have been filed by plaintiffs, including putative classes of direct purchasers, indirect purchasers, and indirect resellers, as well as individual direct and indirect purchasers and certain counties. They allege harm under federal and state laws, including federal and state antitrust laws, state consumer protection laws and unjust enrichment claims. Some of the lawsuits also name as defendants Mylan’s President, including allegations against him with respect to doxycycline hyclate delayed release, and one of Mylan’s sales employees, including allegations against him with respect to certain generic drugs. The lawsuits have been consolidated in an MDL proceeding in the EDPA. Defendants filed motions to dismiss certain complaints that each allege anticompetitive conduct with respect to single drug products. On October 16, 2018, the Court denied the motions with respect to the federal law claims. On February 15, 2019, the Court granted in part and denied in part the motions with respect to the state law claims. On February 21, 2019, Defendants filed a motion to dismiss certain complaints that allege anticompetitive conduct with respect to multiple drug products, which was denied on August 15, 2019. On July 14, 2020, the Court ordered that certain plaintiffs’ complaints regarding three individual drug products proceed as bellwethers. Mylan is named in those plaintiffs’ complaints that regard one of the three individual drug products. A scheduling order has not yet been issued for these matters. The Company believes that the claims in these lawsuits are without merit and intends to defend against them vigorously. Attorneys General Litigation On December 21, 2015, the Company received a subpoena and interrogatories from the Connecticut Office of the Attorney General seeking information relating to the marketing, pricing and sale of certain of the Company’s generic products (including generic doxycycline) and communications with competitors about such products. On December 14, 2016, attorneys general of certain states originally filed a complaint in the United States District Court for the District of Connecticut against several generic pharmaceutical drug manufacturers, including Mylan, alleging anticompetitive conduct with respect to, among other things, doxycycline hyclate delayed release. The complaint has subsequently been amended, including on June 18, 2018, to add attorneys general alleging violations of federal and state antitrust laws, as well as violations of various states’ consumer protection laws. This lawsuit has been transferred to the aforementioned MDL proceeding in the EDPA. The operative complaint includes attorneys general of forty-seven states, the District of Columbia and the Commonwealth of Puerto Rico. Mylan is alleged to have engaged in anticompetitive conduct with respect to doxycycline hyclate delayed release, doxycycline monohydrate, glipizide-metformin, and verapamil. The amended complaint also includes claims asserted by attorneys general of thirty-seven states and the Commonwealth of Puerto Rico against certain individuals, including Mylan’s President, with respect to doxycycline hyclate delayed release. On February 21, 2019, Defendants filed motions to dismiss the amended complaint’s allegations of anticompetitive conduct with respect to multiple drug products, which was denied on August 15, 2019, and the ability of the state attorneys general to seek certain forms of relief under federal antitrust law, which remains pending. On May 31, 2019, Defendants filed a motion to dismiss certain state law claims, which remains pending. On May 10, 2019, certain attorneys general filed a new complaint against various drug manufacturers and individuals, including Mylan and one of its sales employees, alleging anticompetitive conduct with respect to additional generic drugs. On November 1, 2019, the May 10, 2019 complaint was amended, adding additional states as plaintiffs. The operative complaint is brought by attorneys general of forty-eight states, certain territories and the District of Columbia. The amended complaint also includes claims asserted by attorneys general of forty-three states and certain territories against several individuals, including a Mylan sales employee. On July 14, 2020, the Court ordered that this complaint proceed as a bellwether. A scheduling order has not yet been issued for this matter. On November 2, 2020, Defendants filed motions to dismiss the amended complaint. On June 10, 2020, attorneys general of forty-six states, certain territories and the District of Columbia filed a new complaint against drug manufacturers, including Mylan, and individual defendants (none from Mylan), alleging anticompetitive conduct with respect to additional generic drugs. We believe that the claims in these lawsuits are without merit and intend to defend against them vigorously. Securities Related Litigation U.S. Securities Litigation Purported class action complaints were filed in October 2016 against Mylan N.V., Mylan Inc. and certain of their current and former directors and officers (collectively, for purposes of this paragraph, the “defendants”) in the SDNY on behalf of certain purchasers of securities of Mylan N.V. and/or Mylan Inc. on the NASDAQ. The complaints alleged that defendants made false or misleading statements and omissions of purportedly material fact, in violation of federal securities laws, in connection with disclosures relating to Mylan N.V. and Mylan Inc.’s classification of their EpiPen® Auto-Injector as a non-innovator drug for purposes of the Medicaid Drug Rebate Program (“MDRP”). The complaints sought damages, as well as the plaintiffs’ fees and costs. On March 20, 2017, a consolidated amended complaint was filed, alleging substantially similar claims and seeking substantially similar relief, but adding allegations that defendants made false or misleading statements and omissions of purportedly material fact in connection with allegedly anticompetitive conduct with respect to EpiPen® Auto-Injector and certain generic drugs, and alleging violations of both federal securities laws (on behalf of a purported class of certain purchasers of securities of Mylan N.V. and/or Mylan Inc. on the NASDAQ) and Israeli securities laws (on behalf of a purported class of certain purchasers of securities of Mylan N.V. on the Tel Aviv Stock Exchange). On March 28, 2018, defendants’ motion to dismiss the consolidated amended complaint was granted in part (including the dismissal of claims arising under Israeli securities laws) and denied in part. On July 6, 2018, the plaintiffs filed a second amended complaint, including certain current and former directors and officers and additional allegations in connection with purportedly anticompetitive conduct with respect to EpiPen® Auto-Injector and certain generic drugs. On August 6, 2018, defendants filed a motion to dismiss the second amended complaint, which was granted in part and denied in part on March 29, 2019. On June 17, 2019, plaintiffs filed a third amended complaint, including certain current and former directors and employees/officers and additional allegations in connection with purportedly anticompetitive conduct with respect to certain generic drugs. On July 31, 2019, defendants filed a motion to dismiss certain of the claims in the third amended complaint, which was granted in part and denied in part on April 6, 2020. On August 30, 2019, plaintiffs filed a motion for class certification, which was granted on April 6, 2020. The certified class covers all persons or entities that purchased Mylan common stock between February 21, 2012 and May 24, 2019 excluding defendants, current and former officers and directors of Mylan, members of their immediate families and their legal representatives, heirs, successors or assigns, and any entity in which defendants have or had a controlling interest. On February 26, 2019, MYL Litigation Recovery I LLC (“MYL Plaintiff”) (an assignee of entities that purportedly purchased stock of Mylan N.V.) filed an additional complaint against Mylan N.V., Mylan Inc., and certain of their current and former directors and officers in the SDNY asserting allegations pertaining to EpiPen® Auto-Injector under the federal securities laws that overlap in part with those asserted in the third amended complaint identified above. MYL Plaintiff’s complaint seeks damages as well as the plaintiff’s costs. On June 5, 2019, defendants filed a motion to dismiss certain of MYL Plaintiff’s claims, which was granted in part and denied in part on March 30, 2020. On May 6, 2020, MYL Plaintiff filed an amended complaint against Mylan N.V., Mylan Inc., and certain of their current and former officers and directors, including allegations in connection with purportedly anticompetitive conduct with respect to EpiPen® Auto-Injector. MYL Plaintiff subsequently filed a summons on October 30, 2020, naming Mylan N.V., Mylan Inc., and certain current and former directors and employees/officers in New York State Court, County of New York, claiming investment losses suffered as a result of purportedly false and misleading statements in connection with allegedly anticompetitive conduct concerning generic pharmaceuticals. On February 14, 2020, the Abu Dhabi Investment Authority filed a complaint against Mylan N.V. and Mylan Inc. in the SDNY asserting allegations pertaining to EpiPen® Auto-Injector and certain generic drugs under the federal securities laws that overlap with those asserted in the third amended complaint identified above. The Abu Dhabi Investment Authority’s complaint seeks damages as well as the plaintiff’s fees and costs. On June 26, 2020, defendants filed a motion to dismiss certain of plaintiff’s claims. The motion is pending. Beginning in April 2020, Mylan N.V., its directors and certain of its officers were named as defendants in lawsuits filed in federal court, including a putative class action, alleging certain federal securities law violations for purportedly failing to disclose or misrepresenting material information in the definitive proxy statement filed by Mylan N.V. with the SEC in connection with the Combination. The lawsuits generally seek various relief including (i) enjoining the defendants from proceeding with consummating, or closing the Combination and any vote on the Combination unless and until Mylan discloses and disseminates the purportedly material information; (ii) in the event the Combination is consummated, rescinding it and setting it aside or awarding rescissory damages; and (iii) reasonable attorneys and expert fees. Plaintiffs in each of these cases have dismissed their cases against defendants. On June 26, 2020, a putative class action complaint was filed by the Public Employees Retirement System of Mississippi against Mylan N.V. and certain of its directors and officers (collectively for the purposes of this paragraph, the “defendants”) in the U.S. District Court for the Western District of Pennsylvania on behalf of certain purchasers of securities of Mylan N.V. The complaint alleges that defendants made false or misleading statements and omissions of purportedly material fact, in violation of federal securities laws, in connection with disclosures relating to Mylan’s Morgantown manufacturing plant and inspections at the plant by the FDA. The complaint alleges that Mylan N.V.’s stock traded at artificially inflated prices as a result of the allegedly misleading statements and omissions. Plaintiff seeks certification of a class of purchasers of Mylan N.V. securities between February 16, 2016 and May 7, 2019. The complaint seeks damages, as well as the plaintiff’s fees and costs. We believe that the claims in these lawsuits are without merit and intend to defend against them vigorously. Israeli Securities Litigation On October 13, 2016, a purported shareholder of Mylan N.V. filed a lawsuit, together with a motion to certify the lawsuit as a class action on behalf of certain Mylan N.V. shareholders on the Tel Aviv Stock Exchange, against Mylan N.V. and four of its directors and officers (collectively, for purposes of this paragraph, the “defendants”) in the Tel Aviv District Court (Economic Division) (the “Friedman Action”). The plaintiff alleges that the defendants made false or misleading statements and omissions of purportedly material fact in Mylan N.V.’s reports to the Tel Aviv Stock Exchange regarding Mylan N.V.’s classification of its EpiPen® Auto-Injector for purposes of the MDRP, in violation of both U.S. and Israeli securities laws, the Israeli Companies Law and the Israeli Torts Ordinance. The plaintiff seeks damages, among other remedies. On April 30, 2017, another purported shareholder of Mylan N.V. filed a separate lawsuit, together with a motion to certify the lawsuit as a class action on behalf of certain Mylan N.V. shareholders on the Tel Aviv Stock Exchange, in the Tel Aviv District Court (Economic Division), alleging substantially similar claims and seeking substantially similar relief against the defendants and other directors and officers of Mylan N.V., but alleging also that this group of defendants made false or misleading statements and omissions of purportedly material fact in connection with allegedly anticompetitive conduct with respect to EpiPen® Auto-Injector and certain generic drugs, and alleging violations of both U.S. federal securities laws and Israeli law (the “IEC Fund Action”). On April 10, 2018, the Tel Aviv District Court granted the motion filed by plaintiffs in both the Friedman Action and the IEC Fund Action, voluntarily dismissing the Friedman Action and staying the IEC Fund Action until a judgment is issued in the purported class action securities litigation pending in the U.S. We believe that the claims in the IEC Fund Action are without merit and intend to defend against them vigorously. Opioids On July 27, 2017, Mylan N.V. received a subpoena from the DOJ seeking information relating to opioids manufactured, marketed or sold by Mylan during the period from January 1, 2013 to December 31, 2016. On August 29, 2017, Mylan N.V. received a civil investigative demand from the Attorney General of the State of Missouri seeking information relating to opioids manufactured, marketed or sold by Mylan during the period from January 1, 2010 to the present and related subject matter. In November 2019, a subsidiary of Mylan N.V. received a subpoena from the New York Department of Financial Services as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. Mylan is fully cooperating with these subpoena requests. Mylan along with other manufacturers, distributors, pharmacies, pharmacy benefit managers, and individual healthcare providers is a defendant in more than 1,000 cases in the United States and Canada filed by various plaintiffs, including counties, cities and other local governmental entities, asserting civil claims related to sales, marketing and/or distribution practices with respect to prescription opioid products. In addition, lawsuits have been filed as putative class actions including on behalf of children with Neonatal Abstinence Syndrome due to alleged exposure to opioids. The lawsuits generally seek equitable relief and monetary damages (including punitive and/or exemplary damages) based on a variety of legal theories, including various statutory and/or common law claims, such as negligence, public nuisance and unjust enrichment. The vast majority of these lawsuits have been consolidated in an MDL in the U.S. District Court for the Northern District Court of Ohio. A liability-only trial has been scheduled for November 2021 in a coordinated proceeding in West Virginia state court involving Mylan and numerous other manufacturers, distributors, and pharmacies. A trial has also been scheduled in a proceeding in Jefferson County, Missouri on June 6, 2022 involving Mylan and numerous other manufacturers, distributors and pharmacies. Mylan believes that the claims in these lawsuits are without merit and intends to defend against them vigorously. European Commission Proceedings Perindopril On July 9, 2014, the European Commission (the “Commission”) issued a decision finding that Mylan Laboratories Limited and Mylan, as well as several other companies, had violated European Union (“EU”) competition rules relating to the product Perindopril and fined Mylan Laboratories Limited approximately €17.2 million, including approximately €8.0 million jointly and severally with Mylan Inc. The Company paid approximately $21.7 million related to this matter during the fourth quarter of 2014. In September 2014, the Company filed an appeal of the Commission’s decision to the General Court of the EU. A hearing on the appeal before the General Court of the EU was held in June 2017 and the Commission’s decision was affirmed. Mylan appealed the decision to the European Court of Justice (“CJEU”). Mylan has received a notice from an organization representing health insurers in the Netherlands stating an intention to commence follow-on litigation and asserting damages. Citalopram On June 19, 2013, the Commission issued a decision finding that Generics [U.K.] Limited, (“GUK”) as well as several other companies, had violated EU competition rules relating to the product Citalopram and fined GUK approximately €7.8 million, jointly and severally with Merck KGaA. GUK appealed the Commission’s decision to the General Court of the EU. The case is currently on appeal to the CJEU. The U.K. applied and was granted permission to intervene in this proceeding. GUK has received notices from European national health services and health insurers stating an intention to commence follow-on litigation and asserting damages. The national health service in England and Wales has instituted litigation against all parties to the Commission’s decision, including GUK. This litigation has been stayed pending the CJEU’s decision. GUK has also sought indemnification from Merck KGaA with respect to the €7.8 million portion of the fine for which Merck KGaA and GUK were held jointly and severally liable. Merck KGaA has counterclaimed against GUK seeking the same indemnification. In June 2018, the Frankfurt Regional Court issued a judgment dismissing GUK claims against Merck KGaA and ordered GUK to indemnify Merck KGaA with respect to the amount for which the parties were held jointly and s

General (Policies)

General (Policies)	9 Months Ended
General (Policies)	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting Policy	The accompanying unaudited condensed consolidated financial statements (“interim financial statements”) of Mylan N.V. and subsidiaries (“Mylan” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in audited financial statements were condensed or omitted. The interim financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the interim results of operations, comprehensive earnings, financial position, equity and cash flows for the periods presented.
Earnings per Share Policy	Basic earnings (loss) per ordinary share is computed by dividing net earnings (loss) by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per ordinary share is computed by dividing net earnings (loss) by the weighted average number of ordinary shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Policies)	9 Months Ended
Financial Instruments and Risk Management (Policies)	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Value of Financial Instruments Policy	Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: • Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. • Level 2: Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities. • Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value.

Segment Information (Policies)

Segment Information (Policies)	9 Months Ended
Segment Information (Policies)	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Reporting Policy	Mylan reports segment information on a geographic basis. This approach reflects the company’s focus on bringing its broad and diversified portfolio of generic, branded generic, brand-name and over-the-counter products to people in markets everywhere. Our North America segment comprises our operations in the U.S. and Canada. Our Europe segment encompasses our operations in 35 countries, including France, Italy, Germany, the United Kingdom (“U.K.”) and Spain. Our Rest of World segment reflects our operations in more than 120 countries, including Japan, Australia, China, Brazil, Russia, India, South Africa and certain markets in the Middle East and Southeast Asia. The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability. Segment profitability represents segment gross profit less direct research and development (“R&D”) and direct SG&A. Certain general and administrative and R&D expenses not allocated to the segments, including certain special items, net charges for litigation settlements and other contingencies, amortization of intangible assets, impairment charges and other expenses not directly attributable to the segments are reported separately or outside of segment profitability. Items below the earnings from operations line on the Company’s condensed consolidated statements of operations are not presented by segment, since they are excluded from the measure of segment profitability. The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker. The accounting policies of the segments are the same as those described in Note 2 Summary of Significant Accounting Policies included in the 2019 Form 10-K, and Note 3 Recent Accounting Pronouncements, Adoption of New Accounting Standards included in this Form 10-Q. Intersegment revenues are accounted for at current market values and are eliminated at the consolidated level.

Revenue Recognition and Accou_2

Revenue Recognition and Accounts Receivable (Tables)	9 Months Ended
Revenue Recognition and Accounts Receivable (Tables)	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table presents the Company’s net sales by therapeutic franchise for each of our reportable segments for the three and nine months ended September 30, 2020 and 2019, respectively: (In millions) North America Europe Rest of World Total Three Months Ended September 30, 2020 Central Nervous System & Anesthesia $ 181.8 $ 211.5 $ 81.1 $ 474.4 Infectious Disease 37.3 197.2 272.6 507.1 Respiratory & Allergy 284.9 103.1 74.4 462.4 Cardiovascular 58.5 125.6 38.4 222.5 Gastroenterology 41.8 166.2 91.7 299.7 Diabetes & Metabolism 70.8 80.1 36.3 187.2 Dermatology 33.2 72.8 20.3 126.3 Women’s Healthcare 96.0 60.5 34.0 190.5 Oncology 171.4 30.4 40.0 241.8 Immunology 7.9 35.2 10.2 53.3 Other (1) 45.2 41.2 96.5 182.9 Total $ 1,028.8 $ 1,123.8 $ 795.5 $ 2,948.1 Nine Months Ended September 30, 2020 Central Nervous System & Anesthesia $ 484.0 $ 631.0 $ 210.8 $ 1,325.8 Infectious Disease 120.7 320.1 756.8 1,197.6 Respiratory & Allergy 890.4 362.3 165.6 1,418.3 Cardiovascular 184.4 372.7 102.9 660.0 Gastroenterology 121.0 465.6 252.6 839.2 Diabetes & Metabolism 187.4 231.7 89.7 508.8 Dermatology 87.8 215.0 57.2 360.0 Women’s Healthcare 275.9 180.6 84.9 541.4 Oncology 470.8 71.2 103.8 645.8 Immunology 26.9 88.3 27.2 142.4 Other (1) 174.0 142.2 276.7 592.9 Total $ 3,023.3 $ 3,080.7 $ 2,128.2 $ 8,232.2 (In millions) North America Europe Rest of World Total Three Months Ended September 30, 2019 Central Nervous System & Anesthesia $ 155.5 $ 214.3 $ 87.0 $ 456.8 Infectious Disease 28.7 179.0 270.3 478.0 Respiratory & Allergy 308.5 98.2 66.6 473.3 Cardiovascular 63.3 126.2 41.3 230.8 Gastroenterology 30.0 147.9 95.9 273.8 Diabetes & Metabolism 91.3 68.9 34.2 194.4 Dermatology 38.2 75.8 29.3 143.3 Women’s Healthcare 100.4 60.5 26.1 187.0 Oncology 196.1 22.0 42.8 260.9 Immunology 12.3 20.3 10.3 42.9 Other (1) 64.3 32.8 89.9 187.0 Total $ 1,088.6 $ 1,045.9 $ 793.7 $ 2,928.2 Nine Months Ended September 30, 2019 Central Nervous System & Anesthesia $ 426.4 $ 619.3 $ 243.9 $ 1,289.6 Infectious Disease 77.3 299.7 783.0 1,160.0 Respiratory & Allergy 805.3 327.9 166.5 1,299.7 Cardiovascular 159.1 358.6 116.1 633.8 Gastroenterology 94.9 434.9 276.3 806.1 Diabetes & Metabolism 326.1 208.0 110.4 644.5 Dermatology 77.6 217.7 70.7 366.0 Women’s Healthcare 269.5 165.3 65.4 500.2 Oncology 567.8 59.9 107.0 734.7 Immunology 31.4 41.3 27.6 100.3 Other (1) 199.6 198.1 274.4 672.1 Total $ 3,035.0 $ 2,930.7 $ 2,241.3 $ 8,207.0 ____________ (1) Other consists of numerous therapeutic franchises, none of which individually exceeds 5% of consolidated net sales. Variable Consideration and Accounts Receivable The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the three and nine months ended September 30, 2020 and 2019, respectively: Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Gross sales $ 4,986.4 $ 5,051.5 $ 13,868.0 $ 13,841.0 Gross to net adjustments: Chargebacks (967.0) (913.5) (2,616.9) (2,368.8) Rebates, promotional programs and other sales allowances (926.3) (979.2) (2,592.3) (2,709.9) Returns (76.6) (82.3) (193.2) (203.3) Governmental rebate programs (68.4) (148.3) (233.4) (352.0) Total gross to net adjustments $ (2,038.3) $ (2,123.3) $ (5,635.8) $ (5,634.0) Net sales $ 2,948.1 $ 2,928.2 $ 8,232.2 $ 8,207.0
Schedule of Accounts Receivable, Net	Accounts receivable, net was comprised of the following at September 30, 2020 and December 31, 2019, respectively: (In millions) September 30, December 31, Trade receivables, net $ 2,587.8 $ 2,640.1 Other receivables 376.3 418.7 Accounts receivable, net $ 2,964.1 $ 3,058.8

Share-Based Incentive Plan (Tab

Share-Based Incentive Plan (Tables)	9 Months Ended
Share-Based Incentive Plan (Tables)	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock Awards Activity	The following table summarizes stock option and SAR (together, “stock awards”) activity: Number of Shares Under Stock Awards Weighted Average Exercise Price per Share Outstanding at December 31, 2019 6,347,709 $ 36.97 Granted 814,351 17.37 Exercised (27,615) 21.13 Forfeited (337,285) 25.37 Outstanding at September 30, 2020 6,797,160 $ 35.26 Vested and expected to vest at September 30, 2020 6,589,725 $ 35.57 Exercisable at September 30, 2020 5,159,754 $ 38.75
Nonvested Restricted Stock and Restricted Stock Unit Awards Activity	A summary of the status of the Company’s nonvested restricted stock unit awards, including PSUs (collectively, “restricted stock awards”), as of September 30, 2020 and the changes during the nine months ended September 30, 2020 are presented below: Number of Restricted Stock Awards Weighted Average Grant-Date Fair Value per Share Nonvested at December 31, 2019 4,105,689 $ 34.42 Granted 2,978,412 17.46 Released (1,104,737) 36.57 Forfeited (306,108) 39.50 Nonvested at September 30, 2020 5,673,256 $ 24.83

Pensions and Other Postretire_2

Pensions and Other Postretirement Benefits (Tables)	9 Months Ended
Pensions and Other Postretirement Benefits (Tables)	Sep. 30, 2020
Retirement Benefits [Abstract]
Net Periodic Benefit Cost	Components of net periodic benefit cost for the three and nine months ended September 30, 2020 and 2019 were as follows: Pension and Other Postretirement Benefits Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Service cost $ 5.3 $ 5.3 $ 15.9 $ 15.9 Interest cost 2.9 3.8 8.7 11.5 Expected return on plan assets (3.3) (3.0) (10.1) (9.1) Amortization of prior service costs — 0.3 — 0.8 Recognized net actuarial losses (gains) 0.1 (0.2) 0.4 (0.6) Net periodic benefit cost $ 5.0 $ 6.2 $ 14.9 $ 18.5

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
Balance Sheet Components (Tables)	Sep. 30, 2020
Balance Sheet Components [Abstract]
Schedule of Cash, cash equivalents, and restricted cash [Table Text Block]	Cash and restricted cash (In millions) September 30, December 31, September 30, Cash and cash equivalents $ 664.5 $ 475.6 $ 358.9 Restricted cash, included in prepaid expenses and other current assets 2.6 15.5 15.5 Cash, cash equivalents and restricted cash $ 667.1 $ 491.1 $ 374.4
Inventories	Inventories (In millions) September 30, December 31, Raw materials $ 892.6 $ 886.8 Work in process 426.6 417.2 Finished goods 1,702.8 1,366.9 Inventories $ 3,022.0 $ 2,670.9
Prepaid Expenses and Other Current Assets	Prepaid and other current assets (In millions) September 30, December 31, 2019 Prepaid expenses $ 189.1 $ 156.7 Restricted cash 2.6 15.5 Available-for-sale fixed income securities 39.1 26.8 Fair value of financial instruments 51.1 43.3 Equity securities 40.9 39.0 Other current assets 361.3 270.7 Prepaid expenses and other current assets $ 684.1 $ 552.0
Property, Plant and Equipment	Property, plant and equipment, net (In millions) September 30, December 31, 2019 Machinery and equipment $ 2,603.1 $ 2,523.7 Buildings and improvements 1,219.8 1,197.3 Construction in progress 271.9 277.3 Land and improvements 125.5 124.6 Gross property, plant and equipment 4,220.3 4,122.9 Accumulated depreciation 2,162.0 1,973.3 Property, plant and equipment, net $ 2,058.3 $ 2,149.6
Other Assets	Other assets (In millions) September 30, December 31, 2019 Equity method investments, clean energy investments $ 57.6 $ 92.2 Operating lease right-of-use assets 227.9 254.6 Other long-term assets 123.4 58.2 Other assets $ 408.9 $ 405.0
Trade Accounts Payable	ccounts payable (In millions) September 30, December 31, Trade accounts payable $ 900.8 $ 1,061.9 Other payables 547.0 466.2 Accounts payable $ 1,447.8 $ 1,528.1
Other Current Liabilities	Other current liabilities (In millions) September 30, December 31, 2019 Accrued sales allowances $ 697.9 $ 796.5 Legal and professional accruals, including litigation accruals 117.5 138.2 Payroll and employee benefit liabilities 503.2 467.1 Contingent consideration 124.8 120.4 Accrued interest 179.1 59.1 Restructuring 17.1 26.0 Equity method investments, clean energy investments 50.1 47.7 Fair value of financial instruments 17.1 12.9 Operating lease liability 68.5 76.7 Other 470.9 575.3 Other current liabilities $ 2,246.2 $ 2,319.9
Other Noncurrent Liabilities	Other long-term obligations (In millions) September 30, December 31, 2019 Employee benefit liabilities $ 412.2 $ 408.9 Contingent consideration 88.4 130.3 Equity method investments, clean energy investments 13.5 57.2 Tax related items, including contingencies 137.3 109.6 Operating lease liability 156.9 175.7 Other 92.6 79.1 Other long-term obligations $ 900.9 $ 960.8

Equity Method Investments (Tabl

Equity Method Investments (Tables)	9 Months Ended
Equity Method Investments (Tables)	Sep. 30, 2020
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments	Summarized financial information, in the aggregate, for the Company’s significant equity method investments on a 100% basis for the three and nine months ended September 30, 2020 and 2019 are as follows: Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Total revenues $ 113.5 $ 101.6 $ 288.8 $ 274.1 Gross loss (1.4) (1.1) (3.6) (3.1) Operating and non-operating expense 5.2 5.2 14.4 14.3 Net loss $ (6.6) $ (6.3) $ (18.0) $ (17.4)

Earnings (Loss) per Ordinary _2

Earnings (Loss) per Ordinary Share (Tables)	9 Months Ended
Earnings (Loss) per Ordinary Share (Tables)	Sep. 30, 2020
Earnings Per Share [Abstract]
Basic and Diluted Earnings per Ordinary Share Attributable to Mylan N.V.	Basic and diluted earnings (loss) per ordinary share are calculated as follows: Three Months Ended Nine Months Ended September 30, September 30, (In millions, except per share amounts) 2020 2019 2020 2019 Basic earnings (loss) (numerator): Net earnings (loss) $ 185.7 $ 189.8 $ 245.9 $ (3.7) Shares (denominator): Weighted average ordinary shares outstanding 516.9 516.0 516.8 515.5 Basic earnings (loss) per ordinary share $ 0.36 $ 0.37 $ 0.48 $ (0.01) Diluted earnings (loss) (numerator): Net earnings (loss) $ 185.7 $ 189.8 $ 245.9 $ (3.7) Shares (denominator): Weighted average ordinary shares outstanding 516.9 516.0 516.8 515.5 Share-based awards 0.8 0.2 0.5 — Total dilutive shares outstanding 517.7 516.2 517.3 515.5 Net earnings (loss) per diluted ordinary share $ 0.36 $ 0.37 $ 0.48 $ (0.01)

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
Goodwill and Intangible Assets (Tables)	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the nine months ended September 30, 2020 are as follows: (In millions) North America Segment Europe Segment Rest of World Segment Total Balance at December 31, 2019: Goodwill $ 3,708.4 $ 4,548.6 $ 1,718.6 $ 9,975.6 Accumulated impairment losses (385.0) — — (385.0) 3,323.4 4,548.6 1,718.6 9,590.6 Foreign currency translation 33.8 197.5 (4.6) 226.7 $ 3,357.2 $ 4,746.1 $ 1,714.0 $ 9,817.3 Balance at September 30, 2020: Goodwill $ 3,742.2 $ 4,746.1 $ 1,714.0 $ 10,202.3 Accumulated impairment losses (385.0) — — (385.0) $ 3,357.2 $ 4,746.1 $ 1,714.0 $ 9,817.3
Components of Intangible Assets	Intangible assets consist of the following components at September 30, 2020 and December 31, 2019: (In millions) Weighted Average Life (Years) Original Cost Accumulated Amortization Net Book Value September 30, 2020 Product rights, licenses and other (1) 15 $ 20,738.7 $ 9,890.1 $ 10,848.6 In-process research and development 117.2 — 117.2 $ 20,855.9 $ 9,890.1 $ 10,965.8 December 31, 2019 Product rights, licenses and other (1) 15 $ 20,109.1 $ 8,579.5 $ 11,529.6 In-process research and development 120.3 — 120.3 $ 20,229.4 $ 8,579.5 $ 11,649.9 ____________
Finite-lived Intangible Assets Amortization Expense	Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Intangible asset amortization expense $ 368.1 $ 405.6 $ 1,070.9 $ 1,210.3 IPR&D intangible asset impairment charges — — — 29.5 Finite-lived intangible asset impairment charges — 1.9 — 42.3 Total intangible asset amortization expense (including impairment charges) $ 368.1 $ 407.5 $ 1,070.9 $ 1,282.1
Expected Amortization Expense	Intangible asset amortization expense over the remainder of 2020 and for the years ended December 31, 2021 through 2024 is estimated to be as follows (excludes the potential impact of the Combination): (In millions) 2020 $ 369 2021 1,404 2022 1,333 2023 1,166 2024 1,052

Financial Instruments and Ris_3

Financial Instruments and Risk Management (Tables)	9 Months Ended
Financial Instruments and Risk Management (Tables)	Sep. 30, 2020
Derivatives, Fair Value [Line Items]
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2019 to September 30, 2020 is as follows: (In millions) Current Portion (1) Long-Term Portion (2) Total Contingent Consideration Balance at December 31, 2019 $ 120.4 $ 130.3 $ 250.7 Payments (82.1) — (82.1) Reclassifications 52.7 (52.7) — Accretion — 9.0 9.0 Fair value loss (3) 33.8 1.8 35.6 Balance at September 30, 2020 $ 124.8 $ 88.4 $ 213.2 ____________ (1) Included in other current liabilities in the condensed consolidated balance sheets. (2) Included in other long-term obligations in the condensed consolidated balance sheets. (3) Included in litigation settlements and other contingencies, net in the condensed consolidated statements of operations.
Financial Assets and Liabilities Carried at Fair Value	Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above: September 30, 2020 (In millions) Level 1 Level 2 Level 3 Total Recurring fair value measurements Financial Assets Cash equivalents: Money market funds $ 0.9 $ — $ — $ 0.9 Total cash equivalents 0.9 — — 0.9 Equity securities: Exchange traded funds 40.2 — — 40.2 Marketable securities 0.7 — — 0.7 Total equity securities 40.9 — — 40.9 Available-for-sale fixed income investments: Corporate bonds — 19.4 — 19.4 U.S. Treasuries — 12.8 — 12.8 Agency mortgage-backed securities — 1.8 — 1.8 Asset backed securities — 4.5 — 4.5 Other — 0.6 — 0.6 Total available-for-sale fixed income investments — 39.1 — 39.1 Foreign exchange derivative assets — 51.1 — 51.1 Total assets at recurring fair value measurement $ 41.8 $ 90.2 $ — $ 132.0 Financial Liabilities Foreign exchange derivative liabilities — 17.1 — 17.1 Contingent consideration — — 213.2 213.2 Total liabilities at recurring fair value measurement $ — $ 17.1 $ 213.2 $ 230.3 December 31, 2019 (In millions) Level 1 Level 2 Level 3 Total Recurring fair value measurements Financial Assets Cash equivalents: Money market funds $ 0.7 $ — $ — $ 0.7 Total cash equivalents 0.7 — — 0.7 Equity securities: Exchange traded funds 38.3 — — 38.3 Marketable securities 0.7 — — 0.7 Total equity securities 39.0 — — 39.0 Available-for-sale fixed income investments: Corporate bonds — 10.8 — 10.8 U.S. Treasuries — 9.5 — 9.5 Agency mortgage-backed securities — 2.3 — 2.3 Asset backed securities — 3.6 — 3.6 Other — 0.6 — 0.6 Total available-for-sale fixed income investments — 26.8 — 26.8 Foreign exchange derivative assets — 21.0 — 21.0 Interest rate swap derivative assets — 22.3 — 22.3 Total assets at recurring fair value measurement $ 39.7 $ 70.1 $ — $ 109.8 Financial Liabilities Foreign exchange derivative liabilities $ — $ 12.9 $ — $ 12.9 Contingent consideration — — 250.7 250.7 Total liabilities at recurring fair value measurement $ — $ 12.9 $ 250.7 $ 263.6
Fair Value Hedging Relationships
Derivatives, Fair Value [Line Items]
Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations	The Effect of Derivative Instruments in the Condensed Consolidated Statement of Operations Derivatives in Fair Value Hedging Relationships Location of Gain (Loss) Amount of Gain (Loss) Recognized in Earnings on Derivatives (In millions) Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Interest rate swaps Interest expense $ — $ 3.3 $ 22.1 $ 24.3 Total $ — $ 3.3 $ 22.1 $ 24.3 Location of Gain (Loss) Amount of Gain (Loss) Recognized in Earnings on Hedged Items (In millions) Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 2023 Senior Notes (3.125% coupon) Interest expense $ — $ (3.3) $ (22.1) $ (24.3) Total $ — $ (3.3) $ (22.1) $ (24.3)
Cash Flow Hedging
Derivatives, Fair Value [Line Items]
Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations	The Effect of Derivative Instruments in the Condensed Consolidated Statements of Comprehensive Earnings (Loss) Derivatives in Cash Flow Hedging Relationships Amount of Gain (Loss) Recognized in AOCE (Net of Tax) on Derivative Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Foreign currency forward contracts $ 29.5 $ (8.4) $ (0.5) $ 10.9 Total $ 29.5 $ (8.4) $ (0.5) $ 10.9 The Effect of Derivative Instruments in the Condensed Consolidated Statement of Operations Derivatives in Cash Flow Hedging Relationships Location of Gain (Loss) Reclassified from AOCE into Earnings Amount of Gain (Loss) Reclassified from AOCE into Earnings Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Foreign currency forward contracts Net sales $ 5.1 $ 0.4 $ 2.3 $ (1.2) Interest rate swaps Interest expense (1.2) (1.8) (3.4) (5.4) Total $ 3.9 $ (1.4) $ (1.1) $ (6.6)
Net Investment Hedging
Derivatives, Fair Value [Line Items]
Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations	The Effect of Derivative Instruments in the Condensed Consolidated Statements of Comprehensive Earnings (Loss) Derivatives in Net Investment Hedging Relationships Amount of Gain (Loss) Recognized in AOCE Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Foreign currency borrowings and forward contracts $ (109.0) $ 106.2 $ (113.8) $ 126.9 Total $ (109.0) $ 106.2 $ (113.8) $ 126.9
Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The Effect of Derivative Instruments in the Condensed Consolidated Balance Sheets Fair Values of Derivative Instruments Derivatives Designated as Hedging Instruments Asset Derivatives September 30, 2020 December 31, 2019 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Interest rate swaps Prepaid expenses and other current assets $ — Prepaid expenses and other current assets $ 22.3 Foreign currency forward contracts Prepaid expenses and other current assets 12.5 Prepaid expenses and other current assets 12.5 Total $ 12.5 $ 34.8 Liability Derivatives September 30, 2020 December 31, 2019 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Other current liabilities — Other current liabilities — Total $ — $ —
Not Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The Effect of Derivative Instruments in the Condensed Consolidated Balance Sheets Fair Values of Derivative Instruments Derivatives Not Designated as Hedging Instruments Asset Derivatives September 30, 2020 December 31, 2019 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Prepaid expenses and other current assets $ 38.6 Prepaid expenses and other current assets $ 8.5 Total $ 38.6 $ 8.5 Liability Derivatives September 30, 2020 December 31, 2019 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Other current liabilities $ 17.1 Other current liabilities $ 12.9 Total $ 17.1 $ 12.9
Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations	The Effect of Derivative Instruments in the Condensed Consolidated Statement of Operations Derivatives Not Designated as Hedging Instruments Location of Gain (Loss) Recognized in Earnings on Derivatives Amount of Gain (Loss) Recognized in Earnings on Derivatives Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2020 2019 2020 2019 Foreign currency option and forward contracts Other expense, net $ 9.8 $ 15.5 $ 22.9 $ (12.0) Total $ 9.8 $ 15.5 $ 22.9 $ (12.0)

Debt (Tables)

Debt (Tables)	9 Months Ended
Debt (Tables)	Sep. 30, 2020
Debt Disclosure [Abstract]
Summary of Long-Term Debt	A summary of long-term debt is as follows: (In millions) Interest Rate as of September 30, 2020 September 30, December 31, Current portion of long-term debt: 2020 Floating Rate Euro Notes (a) — 560.6 2020 Euro Senior Notes 1.250 % 878.9 840.1 2020 Senior Notes 3.750 % 50.0 50.0 2021 Senior Notes 3.150 % 2,249.6 — Other 6.5 8.3 Deferred financing fees (2.4) (1.4) Current portion of long-term debt $ 3,182.6 $ 1,457.6 Non-current portion of long-term debt: 2021 Senior Notes ** 3.150 % — 2,249.2 2023 Senior Notes (b) * 3.125 % 785.4 771.8 2023 Senior Notes * 4.200 % 499.3 499.1 2024 Euro Senior Notes ** 2.250 % 1,170.4 1,119.3 2025 Euro Senior Notes * 2.125 % 585.1 559.6 2026 Senior Notes 3.950 % 2,239.3 2,238.1 2028 Euro Senior Notes 3.125 % 872.7 834.3 2028 Senior Notes * 4.550 % 748.5 748.4 2043 Senior Notes * 5.400 % 497.3 497.2 2046 Senior Notes ** 5.250 % 999.9 999.8 2048 Senior Notes * 5.200 % 747.7 747.7 Other 5.5 8.9 Deferred financing fees (49.6) (59.1) Long-term debt $ 9,101.5 $ 11,214.3 ____________ (a) The 2020 Floating Rate Euro Notes were repaid at maturity in the second quarter of 2020. The instrument bore interest at a rate of three-month EURIBOR plus 0.50% per annum, reset quarterly. (b) In the first quarter of 2020, the Company terminated interest rate swaps designated as a fair value hedge resulting in net proceeds of approximately $45 million. The fair value adjustment will be amortized to interest expense over the remaining term of the notes. * Instrument was issued by Mylan Inc. ** Instrument was issued by Mylan N.V.
Minimum Repayments on Outstanding Borrowings	Mandatory minimum repayments remaining on the notional amount of outstanding long-term debt at September 30, 2020 were as follows for each of the periods ending December 31: (In millions) Total 2020 $ 929 2021 2,250 2022 — 2023 1,250 2024 1,172 Thereafter 6,715 Total $ 12,316

Comprehensive Earnings (Tables)

Comprehensive Earnings (Tables)	9 Months Ended
Comprehensive Earnings (Tables)	Sep. 30, 2020
Equity [Abstract]
Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss, as reflected on the condensed consolidated balance sheets, is comprised of the following: (In millions) September 30, December 31, Accumulated other comprehensive loss: Net unrealized gain on marketable securities, net of tax $ 1.4 $ 0.6 Net unrecognized loss and prior service cost related to defined benefit plans, net of tax (14.5) (17.4) Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax (31.3) (31.6) Net unrecognized loss on derivatives in net investment hedging relationships, net of tax (188.0) (74.3) Foreign currency translation adjustment (1,191.4) (1,674.5) $ (1,423.8) $ (1,797.2)
Components of Other Comprehensive Loss	Components of accumulated other comprehensive loss, before tax, consist of the following, for the three and nine months ended September 30, 2020 and 2019: Three Months Ended September 30, 2020 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at June 30, 2020, net of tax $ (55.7) $ (79.0) $ 1.3 $ (12.4) $ (1,879.1) $ (2,024.9) Other comprehensive earnings (loss) before reclassifications, before tax 36.4 (114.7) — (1.7) 687.7 607.7 Amounts reclassified from accumulated other comprehensive earnings (loss), before tax: Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales (5.1) (5.1) (5.1) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 1.2 1.2 1.2 Amortization of actuarial loss included in SG&A 0.1 0.1 Net other comprehensive earnings (loss), before tax 32.5 (114.7) — (1.6) 687.7 603.9 Income tax provision (benefit) 8.1 (5.7) (0.1) 0.5 — 2.8 Balance at September 30, 2020, net of tax $ (31.3) $ (188.0) $ 1.4 $ (14.5) $ (1,191.4) $ (1,423.8) Three Months Ended September 30, 2019 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at June 30, 2019, net of tax $ (33.0) $ (110.2) $ 0.7 $ 1.7 $ (1,400.9) $ (1,541.7) Other comprehensive earnings (loss) before reclassifications, before tax (12.0) 111.8 0.1 (0.8) (748.9) (649.8) Amounts reclassified from accumulated other comprehensive loss, before tax: Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales (0.4) (0.4) (0.4) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 1.8 1.8 1.8 Amortization of prior service costs included in SG&A 0.3 0.3 Amortization of actuarial loss included in SG&A (0.2) (0.2) Net other comprehensive earnings (loss), before tax (10.6) 111.8 0.1 (0.7) (748.9) (648.3) Income tax provision (benefit) (4.0) 5.5 — (0.3) — 1.2 Balance at September 30, 2019, net of tax $ (39.6) $ (3.9) $ 0.8 $ 1.3 $ (2,149.8) $ (2,191.2) Nine Months Ended September 30, 2020 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2019, net of tax $ (31.6) $ (74.3) $ 0.6 $ (17.4) $ (1,674.5) $ (1,797.2) Other comprehensive (loss) earnings before reclassifications, before tax (1.3) (119.7) 0.8 3.0 483.1 365.9 Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax: Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales (2.3) (2.3) (2.3) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 3.4 3.4 3.4 Amortization of actuarial loss included in SG&A 0.4 0.4 Net other comprehensive (loss) earnings, before tax (0.2) (119.7) 0.8 3.4 483.1 367.4 Income tax (benefit) provision (0.5) (6.0) — 0.5 — (6.0) Balance at September 30, 2020, net of tax $ (31.3) $ (188.0) $ 1.4 $ (14.5) $ (1,191.4) $ (1,423.8) Nine Months Ended September 30, 2019 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2018, net of tax $ (53.1) $ (130.9) $ — $ 1.7 $ (1,259.0) $ (1,441.3) Other comprehensive earnings (loss) before reclassifications, before tax 18.2 133.6 0.7 (0.7) (890.8) (739.0) Amounts reclassified from accumulated other comprehensive loss, before tax: Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales 1.2 1.2 1.2 Loss on interest rate swaps classified as cash flow hedges, included in interest expense 5.4 5.4 5.4 Amortization of prior service costs included in SG&A 0.8 0.8 Amortization of actuarial loss included in SG&A (0.6) (0.6) Net other comprehensive earnings (loss), before tax 24.8 133.6 0.7 (0.5) (890.8) (732.2) Income tax provision (benefit) 7.9 6.6 (0.1) (0.3) — 14.1 Cumulative effect of the adoption of new accounting standards (3.4) — — (0.2) — (3.6) Balance at September 30, 2019, net of tax $ (39.6) $ (3.9) $ 0.8 $ 1.3 $ (2,149.8) $ (2,191.2)

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
Segment Information (Tables)	Sep. 30, 2020
Segment Reporting [Abstract]
Reconciliation of Segment Information to Total Consolidated Information	Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information. (In millions) North America Europe Rest of World Eliminations Consolidated Three Months Ended September 30, 2020 Net sales $ 1,028.8 $ 1,123.8 $ 795.5 $ — $ 2,948.1 Other revenue 17.4 3.4 3.2 — 24.0 Intersegment revenue 39.3 23.6 126.6 (189.5) — Total $ 1,085.5 $ 1,150.8 $ 925.3 $ (189.5) $ 2,972.1 Segment profitability $ 497.9 $ 348.1 $ 120.3 $ — $ 966.3 Intangible asset amortization expense (368.1) Globally managed research and development costs (31.0) Corporate costs and special items (196.9) Litigation settlements & other contingencies (18.9) Earnings from operations $ 351.4 Nine Months Ended September 30, 2020 Net sales $ 3,023.3 $ 3,080.7 $ 2,128.2 $ — $ 8,232.2 Other revenue 51.8 11.1 27.4 — 90.3 Intersegment revenue 133.4 83.2 387.9 (604.5) — Total $ 3,208.5 $ 3,175.0 $ 2,543.5 $ (604.5) $ 8,322.5 Segment profitability $ 1,447.5 $ 873.2 $ 321.6 $ — $ 2,642.3 Intangible asset amortization expense (1,070.9) Globally managed research and development costs (121.0) Corporate costs and special items (743.6) Litigation settlements & other contingencies (36.5) Earnings from operations $ 670.3 (In millions) North America Europe Rest of World Eliminations Consolidated Three Months Ended September 30, 2019 Net sales $ 1,088.6 $ 1,045.9 $ 793.7 $ — $ 2,928.2 Other revenue 17.6 3.8 12.1 — 33.5 Intersegment revenue 13.9 23.2 134.0 (171.1) — Total $ 1,120.1 $ 1,072.9 $ 939.8 $ (171.1) $ 2,961.7 Segment profitability $ 489.9 $ 325.1 $ 170.3 $ — $ 985.3 Intangible asset amortization expense (405.6) Intangible asset impairment charges (1.9) Globally managed research and development costs (47.3) Corporate costs and special items (258.7) Litigation settlements & other contingencies 51.9 Earnings from operations $ 323.7 Nine Months Ended September 30, 2019 Net sales $ 3,035.0 $ 2,930.7 $ 2,241.3 $ — $ 8,207.0 Other revenue 58.8 12.3 30.6 — 101.7 Intersegment revenue 64.6 66.3 382.1 (513.0) — Total $ 3,158.4 $ 3,009.3 $ 2,654.0 $ (513.0) $ 8,308.7 Segment profitability $ 1,342.3 $ 723.7 $ 435.2 $ — $ 2,501.2 Intangible asset amortization expense (1,210.3) Intangible asset impairment charges (71.8) Globally managed research and development costs (167.8) Corporate costs and special items (638.4) Litigation settlements & other contingencies 30.3 Earnings from operations $ 443.2

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
Restructuring (Tables)	Sep. 30, 2020
Restructuring and Related Activities [Abstract]
Restructuring - employee related	The following table summarizes the restructuring charges and the reserve activity from December 31, 2019 to September 30, 2020: (In millions) Employee Related Costs Other Exit Costs Total Balance at December 31, 2019: $ 26.4 $ 2.8 $ 29.2 Charges (1) 2.9 4.7 7.6 Cash payment (6.0) (0.9) (6.9) Utilization — (3.7) (3.7) Foreign currency translation (0.4) (0.1) (0.5) Balance at March 31, 2020: $ 22.9 $ 2.8 $ 25.7 Charges (1) 0.4 23.2 23.6 Cash payment (3.8) (3.2) (7.0) Utilization — (20.0) (20.0) Foreign currency translation 0.4 0.1 0.5 Balance at June 30, 2020: $ 19.9 $ 2.9 $ 22.8 Charges (1) 4.7 9.8 14.5 Cash payment (3.6) (2.2) (5.8) Utilization — (7.5) (7.5) Foreign currency translation — — — Balance at September 30, 2020: $ 21.0 $ 3.0 $ 24.0 ____________ (1) For the three months ended September 30, 2020, total restructuring charges in North America, Europe and Rest of World were approximately $11.9 million, $2.3 million and $0.3 million, respectively. For the nine months ended September 30, 2020, total restructuring charges in North America, Europe, Rest of World, and corporate were approximately $19.9 million, $23.7 million, $1.6 million, and $0.5 million, respectively.

Revenue Recognition and Accou_3

Revenue Recognition and Accounts Receivable (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Revenue Recognition And Accounts Receivable [Line Items]
Trade receivables, net	$ 2,587.8	$ 2,640.1
Other receivables	376.3	418.7
Accounts receivable, net	2,964.1	3,058.8
Securitized accounts receivable	480.6	407
Receivables Facility
Revenue Recognition And Accounts Receivable [Line Items]
Accounts receivable securitization facility maximum borrowing capacity	400
Note Securitization Facility [Member]
Revenue Recognition And Accounts Receivable [Line Items]
Accounts receivable securitization facility maximum borrowing capacity	200
Variable Consideration
Revenue Recognition And Accounts Receivable [Line Items]
Trade receivables, net	1,502.6	1,512
Other receivables	697.9	796.5
Accounts receivable, net	$ 2,200.5	$ 2,308.5

Revenue Recognition and Accou_4

Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Net sales	$ 2,948.1	$ 2,928.2	$ 8,232.2	$ 8,207
Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	474.4	456.8	1,325.8	1,289.6
Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	507.1	478	1,197.6	1,160
Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	462.4	473.3	1,418.3	1,299.7
Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	222.5	230.8	660	633.8
Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	299.7	273.8	839.2	806.1
Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	187.2	194.4	508.8	644.5
Dermatology
Disaggregation of Revenue [Line Items]
Net sales	126.3	143.3	360	366
Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	190.5	187	541.4	500.2
Oncology
Disaggregation of Revenue [Line Items]
Net sales	241.8	260.9	645.8	734.7
Immunology
Disaggregation of Revenue [Line Items]
Net sales	53.3	42.9	142.4	100.3
Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	182.9	187	592.9	672.1
North America Segment \| Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	181.8	155.5	484	426.4
North America Segment \| Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	37.3	28.7	120.7	77.3
North America Segment \| Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	284.9	308.5	890.4	805.3
North America Segment \| Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	58.5	63.3	184.4	159.1
North America Segment \| Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	41.8	30	121	94.9
North America Segment \| Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	70.8	91.3	187.4	326.1
North America Segment \| Dermatology
Disaggregation of Revenue [Line Items]
Net sales	33.2	38.2	87.8	77.6
North America Segment \| Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	96	100.4	275.9	269.5
North America Segment \| Oncology
Disaggregation of Revenue [Line Items]
Net sales	171.4	196.1	470.8	567.8
North America Segment \| Immunology
Disaggregation of Revenue [Line Items]
Net sales	7.9	12.3	26.9	31.4
North America Segment \| Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	45.2	64.3	174	199.6
Europe Segment \| Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	211.5	214.3	631	619.3
Europe Segment \| Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	197.2	179	320.1	299.7
Europe Segment \| Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	103.1	98.2	362.3	327.9
Europe Segment \| Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	125.6	126.2	372.7	358.6
Europe Segment \| Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	166.2	147.9	465.6	434.9
Europe Segment \| Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	80.1	68.9	231.7	208
Europe Segment \| Dermatology
Disaggregation of Revenue [Line Items]
Net sales	72.8	75.8	215	217.7
Europe Segment \| Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	60.5	60.5	180.6	165.3
Europe Segment \| Oncology
Disaggregation of Revenue [Line Items]
Net sales	30.4	22	71.2	59.9
Europe Segment \| Immunology
Disaggregation of Revenue [Line Items]
Net sales	35.2	20.3	88.3	41.3
Europe Segment \| Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	41.2	32.8	142.2	198.1
Rest of World Segment \| Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	81.1	87	210.8	243.9
Rest of World Segment \| Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	272.6	270.3	756.8	783
Rest of World Segment \| Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	74.4	66.6	165.6	166.5
Rest of World Segment \| Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	38.4	41.3	102.9	116.1
Rest of World Segment \| Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	91.7	95.9	252.6	276.3
Rest of World Segment \| Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	36.3	34.2	89.7	110.4
Rest of World Segment \| Dermatology
Disaggregation of Revenue [Line Items]
Net sales	20.3	29.3	57.2	70.7
Rest of World Segment \| Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	34	26.1	84.9	65.4
Rest of World Segment \| Oncology
Disaggregation of Revenue [Line Items]
Net sales	40	42.8	103.8	107
Rest of World Segment \| Immunology
Disaggregation of Revenue [Line Items]
Net sales	10.2	10.3	27.2	27.6
Rest of World Segment \| Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	96.5	89.9	276.7	274.4
Operating Segment \| North America Segment
Disaggregation of Revenue [Line Items]
Net sales	1,028.8	1,088.6	3,023.3	3,035
Operating Segment \| Europe Segment
Disaggregation of Revenue [Line Items]
Net sales	1,123.8	1,045.9	3,080.7	2,930.7
Operating Segment \| Rest of World Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 795.5	$ 793.7	$ 2,128.2	$ 2,241.3

Revenue Recognition and Accou_5

Revenue Recognition and Accounts Receivable Variable Consideration (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Gross sales	$ 4,986.4	$ 5,051.5	$ 13,868	$ 13,841
Chargebacks	(967)	(913.5)	(2,616.9)	(2,368.8)
Rebates, promotional programs and other sales allowances	(926.3)	(979.2)	(2,592.3)	(2,709.9)
Returns	(76.6)	(82.3)	(193.2)	(203.3)
Medicaid and other governmental rebates	(68.4)	(148.3)	(233.4)	(352)
Sales Revenue, Gross to net adjustments	(2,038.3)	(2,123.3)	(5,635.8)	(5,634)
Net sales	$ 2,948.1	$ 2,928.2	$ 8,232.2	$ 8,207

Revenue Recognition and Accou_6

Revenue Recognition and Accounts Receivable (Accounts Receivable, Net) (Details) - USD ($) $ in Millions	6 Months Ended	9 Months Ended
	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Proceeds from Sale and Collection of Receivables	$ 90.1	$ 123
Trade receivables, net		2,587.8	$ 2,640.1
Other receivables		376.3	418.7
Accounts receivable, net		$ 2,964.1	$ 3,058.8

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements Recent Accounting Pronouncements (Impact of Adoption - ASU 2014-09) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Item Effected [Line Items]
Cost of sales	$ 1,813.6	$ 1,889.3	$ 5,232.2	$ 5,498.5
Income tax provision (benefit)	55.9	(4)	46.4	22.9
Net earnings (loss)	185.7	189.8	245.9	(3.7)
Revenues	2,972.1	2,961.7	8,322.5	8,308.7
Prepaid expenses and other current assets	684.1		684.1			$ 552
Income taxes payable	343.3		343.3			213
Retained earnings	6,277		6,277			6,031.1
Accumulated other comprehensive loss	$ (1,423.8)	$ (2,191.2)	$ (1,423.8)	$ (2,191.2)	$ (2,024.9)	$ (1,797.2)	$ (1,541.7)

Acquisitions and Other Transa_2

Acquisitions and Other Transactions (Narrative) (Details) € in Millions	Jun. 22, 2020USD ($)	Jun. 16, 2020USD ($)	Jul. 29, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2020EUR (€)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Jun. 25, 2021EUR (€)	Jun. 22, 2020EUR (€)	Dec. 31, 2019USD ($)
Business Acquisition [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,500,000,000
Payments of Financing Costs						$ 1,800,000	$ 2,700,000
Delayed draw term loan credit agreement		600,000,000
Contingent consideration				$ 213,200,000		213,200,000				$ 250,700,000
Upjohn Inc.
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired			43.00%
Transaction costs				$ 30,000,000		$ 115,000,000
Extension term of supply contract	4 years
Additional extension term of supply contract	1 year
Aspen Global Incorporated [Member]
Business Acquisition [Line Items]
Amount to acquire business \| €					€ 641.9
Payments to acquire business \| €					€ 263.2
Aspen Global Incorporated [Member] \| Scenario, Plan [Member]
Business Acquisition [Line Items]
Contingent consideration \| €								€ 378.7
Upjohn Inc.
Business Acquisition [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 4,000,000,000
Upjohn Inc. \| United States of America, Dollars
Business Acquisition [Line Items]
Senior Notes	$ 7,450,000,000
Upjohn Inc. \| Euro Member Countries, Euro
Business Acquisition [Line Items]
Senior Notes \| €									€ 3,600
Upjohn Inc. \| Pfizer, Inc.
Business Acquisition [Line Items]
Payments for Business Separation			$ 12,000,000,000
Delayed draw term		18 months
Product \| Upjohn Inc.
Business Acquisition [Line Items]
Number Of Products			20
Upjohn Inc. \| Pfizer, Inc.
Business Acquisition [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent			57.00%

Share-Based Incentive Plan (Nar

Share-Based Incentive Plan (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,797,160		6,347,709
Long-Term Incentive Plan 2003
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares reserved for issuance	55,300,000
Total unrecognized compensation expense, net of estimated forfeitures	$ 78.9
Weighted-average period over which total unrecognized compensation expense expected to be recognized, in years	1 year 6 months
Intrinsic value of stock-based awards exercised and restricted stock units converted	$ 19.1	$ 37.9
Long-Term Incentive Plan 2003 \| Stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award expiration period, in years	10 years
Average remaining contractual term for stock awards outstanding, in years	5 years 3 months 18 days
Average remaining contractual term for stock awards vested and expected to vest, in years	5 years 2 months 12 days
Average remaining contractual term for stock awards exercisable, in years	4 years 2 months 12 days
Long-Term Incentive Plan 2003 \| Stock awards \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years	3 years
Long-Term Incentive Plan 2003 \| Stock awards \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years	4 years

Share-Based Incentive Plan (Sto

Share-Based Incentive Plan (Stock Awards) (Details) - $ / shares	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 35.26	$ 36.97
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	814,351
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 17.37
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(27,615)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 21.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	(337,285)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	$ 25.37
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	6,589,725
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 35.57
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	5,159,754
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 38.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,797,160	6,347,709

Share-Based Incentive Plan (Non

Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details) - Restricted stock awards	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of restricted stock awards, nonvested beginning of period \| shares	4,105,689
Weighted average grant-date fair value per share, nonvested beginning of period \| $ / shares	$ 34.42
Number of restricted stock awards, granted \| shares	2,978,412
Weighted average grant-date fair value per share, granted \| $ / shares	$ 17.46
Number of restricted stock awards, released \| shares	(1,104,737)
Weighted average grant-date fair value per share, released \| $ / shares	$ 36.57
Number of restricted stock awards, forfeited \| shares	(306,108)
Weighted average grant-date fair value per share, forfeited \| $ / shares	$ 39.50
Number of restricted stock awards, nonvested end of period \| shares	5,673,256
Weighted average grant-date fair value per share, nonvested end of period \| $ / shares	$ 24.83

Pension and Other Postretiremen

Pension and Other Postretirement Benefit (Narrative) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plans, Number of Frozen Plans	2
Defined benefit plans, estimated benefit payments, in current fiscal year	$ 35.2
Estimated employer contributions in current year	$ 35.1

Pensions and Other Postretire_3

Pensions and Other Postretirement Benefits (Net Periodic Benefit Costs) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Pension and other postretirement benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 5.3	$ 5.3	$ 15.9	$ 15.9
Interest cost	2.9	3.8	8.7	11.5
Expected return on plan assets	(3.3)	(3)	(10.1)	(9.1)
Amortization of prior service costs	0	0.3	0	0.8
Recognized net actuarial losses (gains)	0.1	(0.2)	0.4	(0.6)
Net periodic benefit cost	5	6.2	$ 14.9	18.5
Defined Benefit Plan Items \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Defined Benefit Plan Disclosure [Line Items]
Amortization of prior service costs	$ (0.1)	$ (0.3)		$ (0.8)

Balance Sheet Components Balanc

Balance Sheet Components Balance Sheet Components (Cash, cash equivalents, and restricted cash) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018
Cash and Cash Equivalents [Abstract]
Restricted cash	$ 2.6	$ 15.5	$ 15.5
Cash and cash equivalents	664.5	475.6	358.9
Cash, cash equivalents and restricted cash	$ 667.1	$ 491.1	$ 374.4	$ 389.3

Balance Sheet Components (Inven

Balance Sheet Components (Inventories) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Balance Sheet Components [Abstract]
Raw materials	$ 892.6	$ 886.8
Work in process	426.6	417.2
Finished goods	1,702.8	1,366.9
Inventories	$ 3,022	$ 2,670.9

Balance Sheet Components (Prepa

Balance Sheet Components (Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Property, Plant and Equipment [Line Items]
Prepaid expenses	$ 189.1	$ 156.7
Restricted cash	2.6	15.5	$ 15.5
Fair value of financial instruments	51.1	43.3
Equity securities	40.9	39
Other current assets	361.3	270.7
Prepaid expenses and other current assets	684.1	552
Available-for-sale fixed income investments
Property, Plant and Equipment [Line Items]
Available-for-sale securities	$ 39.1	$ 26.8

Balance Sheet Components (Prope

Balance Sheet Components (Property, Plant and Equipment) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 4,220.3	$ 4,122.9
Accumulated depreciation	2,162	1,973.3
Property, plant and equipment, net	2,058.3	2,149.6
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,603.1	2,523.7
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,219.8	1,197.3
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	271.9	277.3
Land and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 125.5	$ 124.6

Balance Sheet Components (Other

Balance Sheet Components (Other Assets) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Schedule of Other Assets [Line Items]
Operating lease right-of-use assets	$ 227.9	$ 254.6
Other long-term assets	123.4	58.2
Other assets	408.9	405
Other assets \| Clean energy investments
Schedule of Other Assets [Line Items]
Equity method investments	$ 57.6	$ 92.2

Balance Sheet Components (Trade

Balance Sheet Components (Trade Accounts Payable) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Accounts Payable, Current [Abstract]
Trade accounts payable	$ 900.8	$ 1,061.9
Other payables	547	466.2
Accounts payable	$ 1,447.8	$ 1,528.1

Balance Sheet Components (Oth_2

Balance Sheet Components (Other Current Liabilities) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Schedule of other current liabilities [Line Items]
Other receivables	$ 376.3	$ 418.7
Legal and professional accruals, including litigation accruals	117.5	138.2
Payroll and employee benefit liabilities	503.2	467.1
Contingent consideration	213.2	250.7
Accrued interest	179.1	59.1
Restructuring	17.1	26
Fair value of financial instruments	17.1	12.9
Operating lease liability	68.5	76.7
Other	470.9	575.3
Other current liabilities	2,246.2	2,319.9
Clean energy investments
Schedule of other current liabilities [Line Items]
Other current liabilities	50.1	47.7
Prepaid expenses and other current assets
Schedule of other current liabilities [Line Items]
Contingent consideration	124.8	120.4
Variable Consideration
Schedule of other current liabilities [Line Items]
Other receivables	$ 697.9	$ 796.5

Balance Sheet Components (Oth_3

Balance Sheet Components (Other Long-term Obligations) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Schedule of Other Noncurrent Liabilities [Line Items]
Employee benefit liabilities	$ 412.2	$ 408.9
Contingent consideration	213.2	250.7
Tax related items, including contingencies	137.3	109.6
Operating Lease, Liability, Noncurrent	156.9	175.7
Other	92.6	79.1
Other long-term obligations	900.9	960.8
Clean energy investments
Schedule of Other Noncurrent Liabilities [Line Items]
Other long-term obligations	13.5	57.2
Other long-term obligations
Schedule of Other Noncurrent Liabilities [Line Items]
Contingent consideration	$ 88.4	$ 130.3

Equity Method Investments (Narr

Equity Method Investments (Narrative) (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020USD ($)investment	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)investment	Sep. 30, 2019USD ($)	Sep. 30, 2020
Schedule of Equity Method Investments [Line Items]
Equity method investments summarized financial data basis			100.00%
Loss from equity method investments	$ 2.9	$ 10.4	$ 37.4	$ 43.6
Clean energy investments
Schedule of Equity Method Investments [Line Items]
Number of equity method investments	3		3		3
Gain on equity method investments	$ 15	$ 7

Equity Method Investments (Inco

Equity Method Investments (Income Statement) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Schedule of Equity Method Investments [Line Items]
Revenues	$ 2,972.1	$ 2,961.7	$ 8,322.5	$ 8,308.7
Gross loss	1,158.5	1,072.4	3,090.3	2,810.2
Operating and non-operating expense	241.6	185.8	292.3	19.2
Net earnings (loss)	185.7	189.8	245.9	(3.7)
Equity Method Investments [Member]
Schedule of Equity Method Investments [Line Items]
Revenues	113.5	101.6	288.8	274.1
Gross loss	(1.4)	(1.1)	(3.6)	(3.1)
Operating and non-operating expense	5.2	5.2	14.4	14.3
Net earnings (loss)	$ (6.6)	$ (6.3)	$ (18)	$ (17.4)

Earnings (Loss) per Ordinary _3

Earnings (Loss) per Ordinary Share (Narrative) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Anti-dilutive stock options or restricted stock awards excluded from computation of earnings per share	8.8	10	9.8	9.9

Earnings (Loss) per Ordinary _4

Earnings (Loss) per Ordinary Share (Basic and Diluted Earnings Per Ordinary Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Net earnings (loss)	$ 185.7	$ 189.8	$ 245.9	$ (3.7)
Weighted average ordinary shares outstanding	516.9	516	516.8	515.5
Weighted average number diluted shares outstanding adjustment, stock-based awards and warrants	0.8	0.2	0.5	0
Total dilutive shares outstanding	517.7	516.2	517.3	515.5
Basic earnings (loss) per ordinary share	$ 0.36	$ 0.37	$ 0.48	$ (0.01)
Diluted earnings (loss) per ordinary share	$ 0.36	$ 0.37	$ 0.48	$ (0.01)

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Asset Impairment Charges	$ 0	$ 1.9	$ 0	$ 71.8
Goodwill	$ 9,817.3		$ 9,817.3		$ 9,590.6
Goodwill, Impaired, Change in Estimate, Period			5 years
Fair Value Inputs, Long-term Revenue Growth Rate, Terminal Year			2.00%
Measurement Input, Discount Rate \| Increased Discount Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment Test, Measurement Input, Increase	0.035		0.035
Measurement Input, Discount Rate \| Goodwill
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment Test, Measurement Input	0.110		0.110
Measurement Input, Estimated Tax Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment Test, Measurement Input	0.255		0.255
Measurement Input, Control Premium
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment Test, Measurement Input	0.150		0.150
Measurement Input, Long-term Revenue Growth Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment Test, Measurement Input	0.075		0.075
Measurement Input, Long-term Revenue Growth Rate \| Reduction in Terminal Value Growth Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment Test, Measurement Input, Reduction	0.035		0.035
Europe Segment
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 4,746.1		$ 4,746.1		$ 4,548.6
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	11.00%		11.00%
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount	$ 1,300		$ 1,300
Minimum \| Measurement Input, EBITDA Multiple
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment Test, Measurement Input	8		8
Maximum \| Measurement Input, EBITDA Multiple
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment Test, Measurement Input	9.5		9.5
Rest of World Segment
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 1,650		$ 1,650
Europe Segment
Finite-Lived Intangible Assets [Line Items]
Goodwill	4,430		4,430
North America Brands
Finite-Lived Intangible Assets [Line Items]
Goodwill	650		650
North America Generics
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 2,600		$ 2,600

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Changes in Carrying Amount of Goodwill) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020
Goodwill [Roll Forward]
Goodwill, gross, beginning balance	$ 9,975.6
Accumulated impairment losses, beginning balance	(385)
Foreign currency translation	226.7
Goodwill, net, beginning balance	9,590.6
Accumulated impairment losses, ending balance	(385)
Goodwill, gross, ending balance	10,202.3
Goodwill, net, ending balance	9,590.6	$ 9,817.3
North America Segment
Goodwill [Roll Forward]
Goodwill, gross, beginning balance	3,708.4
Accumulated impairment losses, beginning balance	(385)
Foreign currency translation	33.8
Goodwill, net, beginning balance	3,323.4
Accumulated impairment losses, ending balance	(385)
Goodwill, gross, ending balance	3,742.2
Goodwill, net, ending balance	3,323.4	3,357.2
Europe Segment
Goodwill [Roll Forward]
Goodwill, gross, beginning balance	4,548.6
Accumulated impairment losses, beginning balance	0
Foreign currency translation	197.5
Goodwill, net, beginning balance	4,548.6
Accumulated impairment losses, ending balance	0
Goodwill, gross, ending balance	4,746.1
Goodwill, net, ending balance	4,548.6	4,746.1
Rest of World Segment
Goodwill [Roll Forward]
Goodwill, gross, beginning balance	1,718.6
Accumulated impairment losses, beginning balance	0
Foreign currency translation	(4.6)
Goodwill, net, beginning balance	1,718.6
Accumulated impairment losses, ending balance	0
Goodwill, gross, ending balance	1,714
Goodwill, net, ending balance	$ 1,718.6	$ 1,714

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets (Components of Intangible Assets) (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Intangible Assets by Major Class [Line Items]
IPR&D intangible asset impairment charges	$ 0		$ 0	$ 0	$ 29.5
Finite-lived intangible assets, original cost	20,738.7			20,738.7		$ 20,109.1
Finite-lived intangible assets, accumulated amortization	9,890.1			9,890.1		8,579.5
Finite-lived intangible assets, net book value	10,848.6			10,848.6		11,529.6
In-process research and development	117.2			117.2		120.3
Intangible assets, gross, excluding goodwill	20,855.9			20,855.9		20,229.4
Intangible assets, net book value, excluding goodwill	$ 10,965.8			$ 10,965.8		$ 11,649.9
Patents and technologies
Intangible Assets by Major Class [Line Items]
Finite-lived intangible assets, estimated useful life, in years		15 years		15 years

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets (Amortization Expense) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible asset amortization expense	$ 368,100,000	$ 405,600,000	$ 1,070,900,000	$ 1,210,300,000
IPR&D intangible asset impairment charges	0	0	0	29,500,000
Total intangible asset amortization expense (including impairment charges)	$ 368,100,000	$ 407,500,000	$ 1,070,900,000	1,282,100,000
Impairment of Intangible Assets, Finite-lived				$ 42,300,000

Goodwill and Intangibles Assets

Goodwill and Intangibles Assets (Expected Amortization Expense) (Details) $ in Millions	Sep. 30, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 369
2021	1,404
2022	1,333
2023	1,166
2024	$ 1,052

Financial Instruments and Ris_4

Financial Instruments and Risk Management (Narrative) (Details) € in Millions, $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2020EUR (€)	Sep. 30, 2020USD ($)	Dec. 31, 2019EUR (€)
Derivative [Line Items]
Proceeds from sale of terminated interest rate swaps \| $	$ 45
Pre-tax net losses on cash flow hedges to be reclassified from AOCE into earnings in next twelve months \| $		$ 39
Long-term Debt, Gross \| $				$ 12,316
Senior Notes \| 2020 Euro Senior Notes
Derivative [Line Items]
Stated percentage rate			1.25%	1.25%
Senior Notes \| 2024 Euro Senior Notes
Derivative [Line Items]
Stated percentage rate			2.25%	2.25%
Senior Notes \| 2026 Senior Notes (3.950% coupon)
Derivative [Line Items]
Stated percentage rate			3.95%	3.95%
Senior Notes \| 2028 Euro Senior Notes
Derivative [Line Items]
Stated percentage rate			3.125%	3.125%
Senior Notes \| 2025 Euro Senior Notes [Member]
Derivative [Line Items]
Stated percentage rate			2.125%	2.125%
Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative			€ 2,354		€ 2,354
Long-term debt			3,000
Net Investment Hedging \| 2020 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative			104		104
Long-term debt			750
Net Investment Hedging \| 2024 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative			1,000		1,000
Long-term debt			1,000
Net Investment Hedging \| 2028 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative			750		750
Long-term debt			750
Net Investment Hedging \| 2025 Euro Senior Notes [Member]
Derivative [Line Items]
Notional amount of derivative			500		€ 500
Long-term debt			€ 500
Measurement Input, Discount Rate \| Contingent consideration \| Minimum
Derivative [Line Items]
Discount rates			0.035	0.035
Measurement Input, Discount Rate \| Contingent consideration \| Maximum
Derivative [Line Items]
Discount rates			0.105	0.105

Financial Instruments and Ris_5

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Balance Sheets Fair Value of Derivative Instruments Derivatives Designated As Hedging Instruments) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 51.1	$ 43.3
Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	12.5	34.8
Fair value of financial instruments	0	0
Designated as Hedging Instrument \| Prepaid expenses and other current assets \| Interest rate swaps
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	0	22.3
Designated as Hedging Instrument \| Prepaid expenses and other current assets \| Foreign exchange forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	12.5	12.5
Designated as Hedging Instrument \| Prepaid expenses and other current assets \| Foreign exchange forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 0	$ 0

Financial Instruments and Ris_6

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Balance Sheets Fair Values of Derivative Instruments Derivatives Not Designated As Hedging Instrument) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 51.1	$ 43.3
Fair value of financial instruments	17.1	12.9
Not Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	38.6	8.5
Not Designated as Hedging Instruments \| Prepaid expenses and other current assets \| Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	38.6	8.5
Not Designated as Hedging Instruments \| Other current liabilities \| Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 17.1	$ 12.9

Financial Instruments and Ris_7

Financial Instruments and Risk Management (Effect Of Derivative Instruments on the Condensed Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships) (Details) - Fair Value Hedging Relationships - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Earnings on Derivatives	$ 0	$ 3.3	$ 22.1	$ 24.3
Amount of Gain (Loss) Recognized in Earnings on Hedged Items	0	(3.3)	(22.1)	(24.3)
Interest expense \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Earnings on Derivatives	0	3.3	22.1	24.3
Interest expense \| 2023 Senior Notes (3.125% coupon)
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Earnings on Hedged Items	$ 0	$ (3.3)	$ (22.1)	$ (24.3)

Financial Instruments and Ris_8

Financial Instruments and Risk Management Financial Instruments and Risk Management (Effect Of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships) (Details) (Details) - Cash Flow Hedging - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Derivative [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	$ 29.5	$ (8.4)	$ (0.5)	$ 10.9
Foreign currency forward contracts
Derivative [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	$ 29.5	$ (8.4)	$ (0.5)	$ 10.9

Financial Instruments and Ris_9

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationships (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Gains and Losses on Derivatives \| Net Investment Hedging \| Foreign currency borrowings and forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	$ (109)	$ 106.2	$ (113.8)	$ 126.9

Financial Instruments and Ri_10

Financial Instruments and Risk Management (Effect Of Derivative Instruments on the Condensed Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details) - Cash Flow Hedging - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	$ 29.5	$ (8.4)	$ (0.5)	$ 10.9
Amount of Gain (Loss) Reclassified from AOCE into Earnings	3.9	(1.4)	(1.1)	(6.6)
Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	29.5	(8.4)	(0.5)	10.9
Foreign currency forward contracts \| Net sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Reclassified from AOCE into Earnings	5.1	0.4	2.3	(1.2)
Interest rate swaps \| Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Reclassified from AOCE into Earnings	$ (1.2)	$ (1.8)	$ (3.4)	$ (5.4)

Financial Instruments and Ri_11

Financial Instruments and Risk Management (Effect Of Derivative Instruments on the Condensed Consolidated Statements of Operations, Derivatives Not Designated as Hedging Instruments) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Earnings on Derivatives	$ 9.8	$ 15.5	$ 22.9	$ (12)
Foreign currency forward contracts \| Other expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Earnings on Derivatives	$ 9.8	$ 15.5	$ 22.9	$ (12)

Financial Instruments and Ri_12

Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 0.9	$ 0.7
Equity securities	40.9	39
Total assets at recurring fair value measurement	132	109.8
Fair value of financial instruments	51.1	43.3
Total liabilities at recurring fair value measurement	230.3	263.6
Foreign currency forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative assets	51.1	21
Foreign exchange derivative liabilities	17.1	12.9
Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	213.2	250.7
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0.9	0.7
Exchange traded funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	40.2	38.3
Available-for-sale fixed income investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	39.1	26.8
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	19.4	10.8
U.S. Treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	12.8	9.5
Agency mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	1.8	2.3
Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	4.5	3.6
Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0.6	0.6
Marketable securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0.7	0.7
Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap derivative assets		22.3
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0.9	0.7
Equity securities	40.9	39
Total assets at recurring fair value measurement	41.8	39.7
Level 1 \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0.9	0.7
Level 1 \| Exchange traded funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	40.2	38.3
Level 1 \| Marketable securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0.7	0.7
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at recurring fair value measurement	90.2	70.1
Total liabilities at recurring fair value measurement	17.1	12.9
Level 2 \| Foreign currency forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative assets	51.1	21
Foreign exchange derivative liabilities	17.1	12.9
Level 2 \| Available-for-sale fixed income investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	39.1	26.8
Level 2 \| Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	19.4	10.8
Level 2 \| U.S. Treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	12.8	9.5
Level 2 \| Agency mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	1.8	2.3
Level 2 \| Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	4.5	3.6
Level 2 \| Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0.6	0.6
Level 2 \| Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap derivative assets		22.3
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at recurring fair value measurement	213.2	250.7
Level 3 \| Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	213.2	250.7
Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial instruments	0	0
Fair value of financial instruments	$ 12.5	$ 34.8

Financial Instruments and Ri_13

Financial Instruments and Risk Management Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 213.2	$ 250.7
Business Combination Contingent Consideration Liability Payments	(82.1)
Business Combination, Contingent Consideration Arrangements, Reclassifications	0
Accretion expense	9
Fair value loss	35.6
Prepaid expenses and other current assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	124.8	120.4
Business Combination Contingent Consideration Liability Payments	(82.1)
Business Combination, Contingent Consideration Arrangements, Reclassifications	52.7
Accretion expense	0
Fair value loss	33.8
Other long-term obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	88.4	$ 130.3
Business Combination Contingent Consideration Liability Payments	0
Business Combination, Contingent Consideration Arrangements, Reclassifications	(52.7)
Accretion expense	9
Fair value loss	$ 1.8

Debt (Receivables, Securitizati

Debt (Receivables, Securitization Facility and Commercial Paper) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Jun. 16, 2020
Short-term Debt [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,500,000,000
Receivables Facility
Short-term Debt [Line Items]
Accounts receivable securitization facility maximum borrowing capacity	$ 400,000,000
Note Securitization Facility [Member]
Short-term Debt [Line Items]
Accounts receivable securitization facility maximum borrowing capacity	$ 200,000,000
London Interbank Offered Rate (LIBOR) [Member] \| Receivables Facility
Short-term Debt [Line Items]
Basis spread on variable rate	0.925%
London Interbank Offered Rate (LIBOR) [Member] \| Note Securitization Facility [Member]
Short-term Debt [Line Items]
Basis spread on variable rate	1.00%
Commercial Paper [Member]
Short-term Debt [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,650,000,000
Debt Instrument, Redemption, Description	364

Debt (Summary of Long-Term Debt

Debt (Summary of Long-Term Debt) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Current portion of long-term debt	$ 3,182.6	$ 3,182.6	$ 1,457.6
Unamortized debt issuance expense	(49.6)	(49.6)	(59.1)
Long-term debt	9,101.5	9,101.5	11,214.3
Proceeds from sale of terminated interest rate swaps	45
Other Current Portion of Long-term Debt
Debt Instrument [Line Items]
Current portion of long-term debt	6.5	6.5	8.3
2020 Floating Rate Euro Notes [Domain]
Debt Instrument [Line Items]
Current portion of long-term debt	0	0	560.6
2020 Euro Senior Notes
Debt Instrument [Line Items]
Current portion of long-term debt	878.9	878.9	840.1
2020 Senior Notes (3.750% coupon)
Debt Instrument [Line Items]
Current portion of long-term debt	50	50	50
Other
Debt Instrument [Line Items]
Long-term debt	$ 5.5	$ 5.5	8.9
Senior Notes \| 2020 Floating Rate Euro Notes [Domain]
Debt Instrument [Line Items]
Basis spread on variable rate		0.50%
Senior Notes \| 2020 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	1.25%	1.25%
Senior Notes \| 2020 Senior Notes (3.750% coupon)
Debt Instrument [Line Items]
Stated percentage rate	3.75%	3.75%
Senior Notes \| 2021 Senior Notes (3.150% coupon)
Debt Instrument [Line Items]
Stated percentage rate	3.15%	3.15%
Long-term debt	$ 2,249.6	$ 2,249.6	2,249.2
Senior Notes \| 2023 Senior Notes (3.125% coupon)
Debt Instrument [Line Items]
Stated percentage rate	3.125%	3.125%
Long-term debt	$ 785.4	$ 785.4	771.8
Senior Notes \| 2023 Senior Notes (4.200% coupon)
Debt Instrument [Line Items]
Stated percentage rate	4.20%	4.20%
Long-term debt	$ 499.3	$ 499.3	499.1
Senior Notes \| 2024 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	2.25%	2.25%
Long-term debt	$ 1,170.4	$ 1,170.4	1,119.3
Senior Notes \| 2025 Euro Senior Notes [Member]
Debt Instrument [Line Items]
Stated percentage rate	2.125%	2.125%
Long-term debt	$ 585.1	$ 585.1	559.6
Senior Notes \| 2026 Senior Notes (3.950% coupon)
Debt Instrument [Line Items]
Stated percentage rate	3.95%	3.95%
Long-term debt	$ 2,239.3	$ 2,239.3	2,238.1
Senior Notes \| 2028 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	3.125%	3.125%
Long-term debt	$ 872.7	$ 872.7	834.3
Senior Notes \| SeniorNotesTwoThousandTwentyEight [Member]
Debt Instrument [Line Items]
Stated percentage rate	4.55%	4.55%
Senior Notes \| 2028 Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	$ 748.5	$ 748.5	748.4
Senior Notes \| 2043 Senior Notes (5.400% coupon)
Debt Instrument [Line Items]
Stated percentage rate	5.40%	5.40%
Long-term debt	$ 497.3	$ 497.3	497.2
Senior Notes \| 2046 Senior Notes (5.250% coupon)
Debt Instrument [Line Items]
Stated percentage rate	5.25%	5.25%
Long-term debt	$ 999.9	$ 999.9	999.8
Senior Notes \| 2048 Senior Notes (5.200%)
Debt Instrument [Line Items]
Stated percentage rate	5.20%	5.20%
Senior Notes \| 2048 Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	$ 747.7	$ 747.7	747.7
Current Portion of Long-Term Debt
Debt Instrument [Line Items]
Unamortized debt issuance expense	$ (2.4)	$ (2.4)	$ (1.4)

Debt (2016 and 2018 Revolving F

Debt (2016 and 2018 Revolving Facility and 2016 Term Facility) (Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Jun. 16, 2020	Dec. 31, 2019	Nov. 22, 2016
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,500,000,000
Current portion of long-term debt	$ 3,182,600,000		$ 1,457,600,000
2016 Revolving Credit Facility
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				$ 2,000,000,000
Line of Credit [Member] \| Trailing Four Quarters [Member] \| 2016 Revolving Credit Facility
Debt Instrument [Line Items]
Line of Credit Facility, Covenant Terms	3.75 to 1.00

Debt (Fair Value) (Narrative) (

Debt (Fair Value) (Narrative) (Details) - USD ($) $ in Billions	Sep. 30, 2020	Dec. 31, 2019
Senior Notes
Debt Instrument [Line Items]
Fair value of long-term debt	$ 13.7	$ 13.4

Debt (Minimum Repayments on Out

Debt (Minimum Repayments on Outstanding Borrowings) (Details) $ in Millions	Sep. 30, 2020USD ($)
Debt Disclosure [Abstract]
2020	$ 929
2021	2,250
2022	0
2023	1,250
2024	1,172
Thereafter	6,715
Total	$ 12,316

Comprehensive Earnings (Accumul

Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	$ 55.9	$ (4)	$ 46.4	$ 22.9
Net unrealized gain on marketable securities, net of tax	1.4	0.8	1.4	0.8	$ 1.3	$ 0.6	$ 0.7
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax	14.5	(1.3)	14.5	(1.3)	(12.4)	(17.4)	1.7
Foreign currency translation adjustment	(1,191.4)	(2,149.8)	(1,191.4)	(2,149.8)	(1,879.1)	(1,674.5)	(1,400.9)
Accumulated other comprehensive loss	(1,423.8)	(2,191.2)	(1,423.8)	(2,191.2)	(2,024.9)	(1,797.2)	(1,541.7)
Other comprehensive earnings (loss), before tax	603.9	(648.3)	367.4	(732.2)
Net unrealized gain on marketable securities	0	0.1	0.8	0.7
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	1.6	0.7	(3.4)	0.5
Sales Revenue, Goods, Net	2,948.1	2,928.2	8,232.2	8,207
Interest expense	117.3	128.9	353.4	391.3
Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gain (loss) on derivatives	32.5	(10.6)	(0.2)
Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulate Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Net Investment Hedges, Effect Net of Taxx	(188)	(3.9)	(188)	(3.9)	(79)	(74.3)	(110.2)
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)				14.1
Accumulated other comprehensive loss		(2,191.2)		(2,191.2)				$ (1,441.3)
Other comprehensive earnings (loss) before reclassifications, before tax	607.7	(649.8)	365.9	(739)
Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)				7.9
Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax		(39.6)		(39.6)				(53.1)
Other comprehensive earnings (loss) before reclassifications, before tax				18.2
Gains and Losses on Derivatives \| Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	8.1	(4)	(0.5)
Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax	(31.3)	(39.6)	(31.3)	(39.6)	$ (55.7)	$ (31.6)	$ (33)
Other comprehensive earnings (loss) before reclassifications, before tax	36.4	(12)	(1.3)
Gains and Losses on Derivatives \| Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	(5.7)	5.5	(6)	6.6
Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax		(3.9)		(3.9)				(130.9)
Other comprehensive earnings (loss) before reclassifications, before tax				133.6
Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)				(0.1)
Net unrealized gain on marketable securities, net of tax		0.8		0.8				0
Other comprehensive earnings (loss) before reclassifications, before tax				0.7
Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)				0.3
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax		1.3		1.3				1.7
Other comprehensive earnings (loss) before reclassifications, before tax	(1.7)	(0.8)	3	(0.7)
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)				0
Foreign currency translation adjustment		(2,149.8)		(2,149.8)				$ (1,259)
Other comprehensive earnings (loss) before reclassifications, before tax	687.7	(748.9)	483.1
Reclassification out of Accumulated Other Comprehensive Income [Member] \| AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	2.8	1.2	(6)
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax	(0.1)	(0.3)		(0.8)
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax		0.2	(0.4)	0.6
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gain (loss) on derivatives				24.8
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	(0.1)	0	0
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	0.5	(0.3)	0.5
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax				0.5
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax	0.1	0.3		0.8
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	0	0	0
Other comprehensive earnings (loss), before tax				(890.8)
Mylan N.V. \| Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gain (loss) on derivatives	(114.7)	111.8	(119.7)	133.6
Foreign currency forward contracts \| Gains and Losses on Derivatives \| Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sales Revenue, Goods, Net	(5.1)	(0.4)	(2.3)
Foreign currency forward contracts \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sales Revenue, Goods, Net	(5.1)	(0.4)	(2.3)	1.2
Foreign currency forward contracts \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sales Revenue, Goods, Net	(5.1)	(0.4)	(2.3)	1.2
Interest rate swaps \| Gains and Losses on Derivatives \| Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.2	1.8	3.4
Interest rate swaps \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.2	1.8	3.4	5.4
Interest rate swaps \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.2	1.8	3.4	5.4
Pension and other postretirement benefits
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax	0	(0.3)	0	(0.8)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement	$ (0.1)	$ 0.2	$ (0.4)	$ 0.6

Comprehensive Earnings (Compone

Comprehensive Earnings (Components Of Other Comprehensive Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrealized gain (loss) on marketable securities, net of tax, beginning of period	$ 1.3	$ 0.7	$ 0.6
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax	14.5	(1.3)	14.5	$ (1.3)	$ 14.5	$ (12.4)	$ (17.4)	$ (1.3)	$ 1.7
Foreign currency translation adjustment, beginning of period	(1,879.1)	(1,400.9)	(1,674.5)
Accumulated other comprehensive loss, net of tax, beginning of period	(2,024.9)	(1,541.7)	(1,797.2)
Net sales	2,948.1	2,928.2	8,232.2	8,207
Interest expense	117.3	128.9	353.4	391.3
Net unrealized gain on marketable securities	0	0.1	0.8	0.7
Change in unrecognized gain and prior service cost related to defined benefit plans	(1.6)	(0.7)	3.4	(0.5)
Other comprehensive earnings (loss), before tax	603.9	(648.3)	367.4	(732.2)
Income Tax Expense (Benefit)	55.9	(4)	46.4	22.9
Net unrealized gain (loss) on marketable securities, net of tax, end of period	1.4	0.8	1.4	0.8
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, end of period	14.5	(1.3)	14.5	(1.3)
Foreign currency translation adjustment, end of period	(1,191.4)	(2,149.8)	(1,191.4)	(2,149.8)
Accumulated other comprehensive loss, net of tax, end of period	(1,423.8)	(2,191.2)	(1,423.8)	(2,191.2)
Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period				(53.1)
Other comprehensive earnings (loss) before reclassifications, before tax				18.2
Income Tax Expense (Benefit)				7.9
Net unrecognized gains (losses) on derivatives, net of tax, end of period		(39.6)		(39.6)
Gains and Losses on Derivatives \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses on derivatives in net investment hedging relationships, net of tax				24.8
Gains and Losses on Derivatives \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Foreign currency forward contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(5.1)	(0.4)	(2.3)	1.2
Gains and Losses on Derivatives \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.2	1.8	3.4	5.4
Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrealized gain (loss) on marketable securities, net of tax, beginning of period				0
Other comprehensive earnings (loss) before reclassifications, before tax				0.7
Income Tax Expense (Benefit)				(0.1)
Net unrealized gain (loss) on marketable securities, net of tax, end of period		0.8		0.8
Gains and Losses on Marketable Securities \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income Tax Expense (Benefit)	(0.1)	0	0
Gains and Losses on Marketable Securities \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrealized gain (loss) on marketable securities, net of tax, end of period		0		0
Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax		1.3		1.3				1.3		$ 1.7
Other comprehensive earnings (loss) before reclassifications, before tax	(1.7)	(0.8)	3	(0.7)
Income Tax Expense (Benefit)				0.3
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, end of period		1.3		1.3
Defined Benefit Plan Items \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs	(0.1)	(0.3)		(0.8)
Change in unrecognized gain and prior service cost related to defined benefit plans				(0.5)
Income Tax Expense (Benefit)	0.5	(0.3)	0.5
Defined Benefit Plan Items \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax		0.2		0.2				0.2
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, end of period		0.2		0.2
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation adjustment, beginning of period				(1,259)
Other comprehensive earnings (loss) before reclassifications, before tax	687.7	(748.9)	483.1
Income Tax Expense (Benefit)				0
Foreign currency translation adjustment, end of period		(2,149.8)		(2,149.8)
Foreign Currency Translation Adjustment \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive earnings (loss), before tax				(890.8)
Income Tax Expense (Benefit)	0	0	0
Foreign Currency Translation Adjustment \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation adjustment, end of period		0		0
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net of tax, beginning of period				(1,441.3)
Other comprehensive earnings (loss) before reclassifications, before tax	607.7	(649.8)	365.9	(739)
Income Tax Expense (Benefit)				14.1
Accumulated other comprehensive loss, net of tax, end of period		(2,191.2)		(2,191.2)
AOCI Attributable to Parent [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs	0.1	0.3		0.8
Other comprehensive earnings (loss), reclassification adjustment from AOCE, pension and other postretirement benefit plans, for net gain (loss), before tax		(0.2)	0.4	(0.6)
Income Tax Expense (Benefit)	2.8	1.2	(6)
AOCI Attributable to Parent [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net of tax, end of period		(3.6)		(3.6)
AOCI Attributable to Parent [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Foreign currency forward contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(5.1)	(0.4)	(2.3)	1.2
AOCI Attributable to Parent [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.2	1.8	3.4	5.4
Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses on derivatives in net investment hedging relationships, net of tax	32.5	(10.6)	(0.2)
Other comprehensive income (loss), derivatives qualifying as hedges, before tax	32.5	(10.6)	(0.2)	24.8
Cash Flow Hedging \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period	(55.7)	(33)	(31.6)
Other comprehensive earnings (loss) before reclassifications, before tax	36.4	(12)	(1.3)
Income Tax Expense (Benefit)	8.1	(4)	(0.5)
Net unrecognized gains (losses) on derivatives, net of tax, end of period	(31.3)	(39.6)	(31.3)	(39.6)
Cash Flow Hedging \| Gains and Losses on Derivatives \| Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, end of period		(3.4)		(3.4)
Cash Flow Hedging \| Gains and Losses on Derivatives \| Foreign currency forward contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(5.1)	(0.4)	(2.3)
Cash Flow Hedging \| Gains and Losses on Derivatives \| Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.2	1.8	3.4
Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulate Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Net Investment Hedges, Effect Net of Taxx					$ (188)	$ (79)	$ (74.3)	$ (3.9)	$ (110.2)
Other comprehensive income (loss), derivatives qualifying as hedges, before tax	(114.7)	111.8	(119.7)	133.6
Net Investment Hedging \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period				(130.9)
Other comprehensive earnings (loss) before reclassifications, before tax				133.6
Income Tax Expense (Benefit)	(5.7)	5.5	(6)	6.6
Net unrecognized gains (losses) on derivatives, net of tax, end of period		(3.9)		(3.9)
Net Investment Hedging \| Gains and Losses on Derivatives \| Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, end of period		0		0
Mylan N.V. \| Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses on derivatives in net investment hedging relationships, net of tax	(114.7)	111.8	(119.7)	133.6
Pension and other postretirement benefits
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs	0	0.3	0	0.8
Recognized net actuarial losses (gains)	$ 0.1	$ (0.2)	$ 0.4	$ (0.6)

Segment Information (Narrative)

Segment Information (Narrative) (Details)	Sep. 30, 2020country
Europe Segment
Segment Reporting Information [Line Items]
Number of Countries in which Entity Operates	35
Rest of World Segment
Segment Reporting Information [Line Items]
Number of Countries in which Entity Operates	120

Segment Information (Reconcilia

Segment Information (Reconciliation Of Segment Information To Total Consolidated Information) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	$ 2,948.1	$ 2,928.2	$ 8,232.2	$ 8,207
Revenues	2,972.1	2,961.7	8,322.5	8,308.7
Amortization of Intangible Assets	(368.1)	(405.6)	(1,070.9)	(1,210.3)
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	0	0	0	(29.5)
Research and development	(129.8)	(167.9)	(400.3)	(488.1)
Litigation settlements and other contingencies, net	(18.9)	51.9	(36.5)	30.3
Earnings from operations	351.4	323.7	670.3	443.2
Other revenue
Segment Reporting Information [Line Items]
Segment profitability	966.3	985.3	2,642.3	2,501.2
Amortization of Intangible Assets	(368.1)	(405.6)	(1,070.9)	(1,210.3)
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)		1.9		71.8
Research and development	(31)	(47.3)	(121)	(167.8)
Corporate costs	(196.9)	(258.7)	(743.6)	(638.4)
Litigation settlements and other contingencies, net	(18.9)	51.9	(36.5)	30.3
Intersegment revenue
Segment Reporting Information [Line Items]
Revenues	(189.5)	(171.1)	(604.5)	(513)
Corporate / Other
Segment Reporting Information [Line Items]
Revenues	(189.5)	(171.1)	(604.5)	(513)
Segment profitability	0	0	0	0
North America Segment
Segment Reporting Information [Line Items]
Revenues	1,085.5	1,120.1	3,208.5	3,158.4
North America Segment \| Operating Segment
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	1,028.8	1,088.6	3,023.3	3,035
Segment profitability	497.9	489.9	1,447.5	1,342.3
North America Segment \| Intersegment revenue
Segment Reporting Information [Line Items]
Revenues	39.3	13.9	133.4	64.6
Europe Segment
Segment Reporting Information [Line Items]
Revenues	1,150.8	1,072.9	3,175	3,009.3
Europe Segment \| Operating Segment
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	1,123.8	1,045.9	3,080.7	2,930.7
Segment profitability	348.1	325.1	873.2	723.7
Europe Segment \| Intersegment revenue
Segment Reporting Information [Line Items]
Revenues	23.6	23.2	83.2	66.3
Rest of World Segment
Segment Reporting Information [Line Items]
Revenues	925.3	939.8	2,543.5	2,654
Rest of World Segment \| Operating Segment
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	795.5	793.7	2,128.2	2,241.3
Segment profitability	120.3	170.3	321.6	435.2
Rest of World Segment \| Intersegment revenue
Segment Reporting Information [Line Items]
Revenues	126.6	134	387.9	382.1
Other Revenues
Segment Reporting Information [Line Items]
Revenues	24	33.5	90.3	101.7
Other Revenues \| North America Segment \| Other revenue
Segment Reporting Information [Line Items]
Revenues	17.4	17.6	51.8	58.8
Other Revenues \| Europe Segment \| Other revenue
Segment Reporting Information [Line Items]
Revenues	3.4	3.8	11.1	12.3
Other Revenues \| Rest of World Segment \| Other revenue
Segment Reporting Information [Line Items]
Revenues	$ 3.2	$ 12.1	$ 27.4	$ 30.6

Restructuring (Restructuring Ch

Restructuring (Restructuring Charges) (Details) - USD ($)	3 Months Ended			9 Months Ended
Restructuring (Restructuring Charges) (Details) - USD ($)	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 22,800,000	$ 25,700,000	$ 29,200,000	$ 29,200,000
Charges	14,500,000	23,600,000	7,600,000
Cash payment	(5,800,000)	(7,000,000)	(6,900,000)
Utilization	(7,500,000)	(20,000,000)	(3,700,000)
Foreign currency translation	0	500,000	(500,000)
Ending Balance	24,000,000	22,800,000	25,700,000	24,000,000
Restructuring Reserve, Current	17,100,000			17,100,000	$ 26,000,000
North America Segment
Restructuring Reserve [Roll Forward]
Charges	11,900,000			19,900,000
Europe Segment
Restructuring Reserve [Roll Forward]
Charges				23,700,000
Rest of World Segment
Restructuring Reserve [Roll Forward]
Charges	300,000			1,600,000
Corporate / Other
Restructuring Reserve [Roll Forward]
Charges				500,000
Europe [Member]
Restructuring Reserve [Roll Forward]
Charges	2,300,000
Employee Related Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	19,900,000	22,900,000	26,400,000	26,400,000
Charges	4,700,000	400,000	2,900,000
Cash payment	(3,600,000)	(3,800,000)	(6,000,000)
Utilization	0	0	0
Foreign currency translation	0	400,000	(400,000)
Ending Balance	21,000,000	19,900,000	22,900,000	21,000,000
Other Exit Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	2,900,000	2,800,000	2,800,000	2,800,000
Charges	9,800,000	23,200,000	4,700,000
Cash payment	(2,200,000)	(3,200,000)	(900,000)
Utilization	(7,500,000)	(20,000,000)	(3,700,000)
Foreign currency translation	0	100,000	(100,000)
Ending Balance	$ 3,000,000	$ 2,900,000	$ 2,800,000	$ 3,000,000

Collaboration and Licensing A_2

Collaboration and Licensing Agreements (Details) - USD ($)	3 Months Ended		9 Months Ended
Collaboration and Licensing Agreements (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and Development Expense	$ 129,800,000	$ 167,900,000	$ 400,300,000	$ 488,100,000
Momenta [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and Development Expense			30,000,000
Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments			425,000,000
Maximum \| Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments			$ 40,000,000

Income Taxes Income Taxes Discl

Income Taxes Income Taxes Disclosure (Details) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
Income Taxes Income Taxes Disclosure (Details) - USD ($)	Sep. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2021	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Income Tax Contingency [Line Items]
Liability for Uncertainty in Income Taxes, Current			$ 140,000,000			$ 15,000,000
Increase to the Income Tax Provision			$ 129,900,000
Increase in liability for uncertain tax positions		$ 89,200,000			$ 126,900,000
Reduction in liability for Unrecognized Tax Benefits							$ 46,100,000
Scenario, Forecast
Income Tax Contingency [Line Items]
Expected reduction to tax expense by CARES Act				$ 27,000,000
Scenario, Adjustment [Member]
Income Tax Contingency [Line Items]
Expected reduction to tax expense by CARES Act	$ 16,500,000

Litigation (Pricing and Medicai

Litigation (Pricing and Medicaid Litigation) (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Loss Contingencies [Line Items]
Other current liabilities	$ 2,246.2	$ 2,319.9

Litigation (Modafinil Antitrust

Litigation (Modafinil Antitrust Litigation and FTC Inquiry) (Narrative) (Details) - Modafinil Antitrust Litigation and FTC Inquiry	Jul. 10, 2015other_drug_manufacturers	Apr. 27, 2006other_drug_manufacturers	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)
Loss Contingencies [Line Items]
Loss Contingency, Loss in Period			$ 18,000,000
Loss Contingency Accrual				$ 14,400,000
Other drug manufacturers
Loss Contingencies [Line Items]
Number of defendants \| other_drug_manufacturers	3	4

Litigation (MDRP Classification

Litigation (MDRP Classification of EpiPen Auto-Injector and EpiPen Jr Auto-Injector) (Details) $ in Millions	Sep. 30, 2020USD ($)
Prepaid expenses and other current assets
Loss Contingencies [Line Items]
Estimated litigation liability	$ 10
EpiPen Auto Injector Civil Litigation [Member]
Loss Contingencies [Line Items]
Number of states	17

Litigation (Drug Pricing Matter

Litigation (Drug Pricing Matters) (Details)	Sep. 30, 2020
Multi District Litigation [Member]
Loss Contingencies [Line Items]
Number of states	47
Anticompetitive Conduct with Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Glipizide-Metformin and Verapamil [Member]
Loss Contingencies [Line Items]
Number of states	37
Anticompetitive Conduct with Generic Drugs [Member]
Loss Contingencies [Line Items]
Number of states	48
Amended Anticompetitive Conduct with Generic Drugs [Member]
Loss Contingencies [Line Items]
Number of states	43

Litigation (European Commission

Litigation (European Commission Proceedings) (Narrative) (Details) € in Millions, $ in Millions	Jul. 09, 2014EUR (€)	Jun. 19, 2013EUR (€)	Jun. 30, 2015USD ($)	Sep. 30, 2020USD ($)
European Commission Proceedings - Perindorpril \| Antitrust Proceedings \| Mylan Laboratories Limited
Loss Contingencies [Line Items]
Damages to be paid	€ 17.2
European Commission Proceedings - Perindorpril \| Antitrust Proceedings \| Mylan
Loss Contingencies [Line Items]
Damages to be paid	€ 8		$ 21.7
European Union Commission Proceedings - Citalopram
Loss Contingencies [Line Items]
Damages awarded		€ 7.8
Loss Contingency Accrual \| $				$ 7.4

Litigation (U.K. Competition an

Litigation (U.K. Competition and Markets Authority) (Narrative) (Details) - U.K. Competition and Markets Authority Proceedings Paroxetine £ in Millions	Feb. 12, 2016GBP (£)
Loss Contingencies [Line Items]
Damages awarded	£ 5.8
Mylan
Loss Contingencies [Line Items]
Damages awarded	£ 2.7

Litigation (Product Liability)

Litigation (Product Liability) (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Product Liability
Loss Contingencies [Line Items]
Loss Contingency Accrual	$ 12.8	$ 14.5

Litigation (Intellectual Proper

Litigation (Intellectual Property) (Narrative) (Details)	9 Months Ended
Litigation (Intellectual Property) (Narrative) (Details)	Sep. 30, 2020increase
Intellectual Property
Loss Contingencies [Line Items]
Number of times damages may be increased in cases of willful infringement	3

Litigation (Other Litigation) (

Litigation (Other Litigation) (Narrative) (Details) $ in Millions	Oct. 13, 2016	Sep. 30, 2020USD ($)
Loss Contingencies [Line Items]
Number of cases		1,000
Other Litigation
Loss Contingencies [Line Items]
Loss Contingency Accrual		$ 8
EpiPen Israeli Securities Litigation [Member]
Loss Contingencies [Line Items]
Number of defendants	4
Amended Anticompetitive Conduct with Generic Drugs [Member]
Loss Contingencies [Line Items]
Number of states		43
Anticompetitive conduct with respect to additional generic drugs [Member]
Loss Contingencies [Line Items]
Number of states		46